In vitro effects of endogenous and exogenous cannabinoids on insulin resistance and secretion by Gallant, Megan
i 
 
IN VITRO EFFECTS OF ENDOGENOUS AND 
EXOGENOUS CANNABINOIDS ON INSULIN 
RESISTANCE AND SECRETION 
 
By 
 
Megan Gallant 
 
 
Submitted in fulfilment of the requirements for the 
degree Magister Scientiae in the Faculty of Science 
at the Nelson Mandela Metropolitan University 
 
January 2009 
 
Supervisor: Mrs. R. A. Levendal 
Co-Supervisor: Prof. C.L. Frost 
 ii 
 
Contents           Page 
Abstract ........................................................................................................ vii 
Acknowledgements .................................................................................... viii 
List of Figures ............................................................................................... ix 
List of Tables .................................................................................................. x 
List of abbreviations ..................................................................................... xi 
Part 1: Literature Survey ............................................................................... 1 
Chapter 1: Introduction ................................................................................. 2 
1.1 Metabolic syndrome and some of its components .................................. 2 
1.2 Insulin: Structure and secretion .............................................................. 5 
1.2.1 Structure of insulin ........................................................................... 5 
1.2.2 Synthesis of insulin .......................................................................... 5 
1.2.3 Insulin secretion ............................................................................... 6 
1.3 Insulin signaling ...................................................................................... 7 
1.3.1 Inhibition of insulin signaling .......................................................... 11 
1.4 Factors contributing to insulin resistance ............................................. 14 
1.4.1 Tumor necrosis factor-α ................................................................. 14 
1.4.2 Hyperinsulinaemia ......................................................................... 14 
1.5 Gene markers of insulin resistance ...................................................... 15 
1.5.1 Insulin Receptor 1 and 2 ................................................................ 15 
1.5.2 Glucose Transporter 4 ................................................................... 15 
1.6 Adipokines ............................................................................................ 16 
 iii 
1.6.1 Adiponectin .................................................................................... 17 
1.6.2 Leptin ............................................................................................. 21 
1.7 Cytokines.............................................................................................. 23 
1.7.1 Tumor necrosis factor-α ................................................................. 24 
1.7.2 Interleukin-6 ................................................................................... 25 
1.8 Cannabis .............................................................................................. 26 
1.8.1 Cannabinoid Receptors ................................................................. 26 
1.8.2 Endocannabinoids ......................................................................... 28 
1.8.3 Endocannabinoid System .............................................................. 29 
1.8.4 CB1 receptor antagonist ................................................................ 32 
Chapter 2: Aim ............................................................................................. 33 
2.1 Objectives............................................................................................. 33 
Part 2: Insulin resistant studies .................................................................. 34 
Chapter 3: Methods and Materials .............................................................. 35 
3.1 Extraction and quantification of THC in extract ..................................... 35 
3.1.1 Chloroform extract procedure ........................................................ 35 
3.1.2 HPLC Quantification THC in the organic extract ............................ 35 
3.2 Maintenance of cells lines .................................................................... 36 
3.3 MTT Cytotoxicity studies ...................................................................... 36 
3.4 Glucose uptake studies ........................................................................ 38 
3.5 Inducing insulin resistance ................................................................... 40 
3.5.1 Insulin resistance in 3T3-L1 cells ................................................... 40 
3.5.2 Insulin resistance in C2C12 cells ................................................... 40 
 iv 
3.5.3 In vitro studies using insulin resistant 3T3-L1 and C2C12 cells ..... 40 
3.6 Adipokine secretion studies .................................................................. 41 
3.7 Experiments for RT-PCR ...................................................................... 43 
3.7.1 Total RNA isolation and Quantification .......................................... 43 
3.7.2. cDNA synthesis ............................................................................ 44 
3.7.3 RT- PCR ........................................................................................ 45 
3.8 Experiments for western blot analysis .................................................. 47 
3.8.1 BCA assay ..................................................................................... 47 
3.8.2 SDS-PAGE and Protein transfer .................................................... 48 
3.9 Statistical Analysis ................................................................................ 50 
Chapter 4: Results ....................................................................................... 51 
4.1 MTT cytotoxic assay ............................................................................. 51 
4.2 Glucose uptake studies ........................................................................ 52 
4.2.1 Non-Insulin resistant studies .......................................................... 52 
4.2.2 Insulin resistant studies.................................................................. 54 
4.3 Adipokine assay ................................................................................... 55 
4.4 RT-PCR studies ................................................................................... 56 
4.4.1 IRS-1 gene expression .................................................................. 57 
4.4.2 Glut- 4 gene expression ................................................................. 58 
4.5 Western Blot analysis ........................................................................... 60 
4.5.1 IRS-1 Western blot analysis ........................................................... 60 
3T3-L1 .................................................................................................... 60 
C2C12 .................................................................................................... 60 
 v 
4.5.2 Phosphorylated IRS-1 Western blot analysis ................................. 61 
3T3-L1 .................................................................................................... 61 
C2C12 .................................................................................................... 61 
4.5.3 PI3K Western blot analysis ............................................................ 62 
3T3-L1 .................................................................................................... 62 
C2C12 .................................................................................................... 62 
4.5.4 Phosphorylated PI3K Western blot analysis .................................. 62 
3T3-L1 .................................................................................................... 63 
C2C12 .................................................................................................... 63 
Chapter 5: Discussion of insulin resistance results ................................. 64 
PART 3: INSULIN SECRETION STUDIES ................................................... 74 
Chapter 6: Methods and Materials .............................................................. 75 
6.1 Extraction and quantification of THC in extract ..................................... 75 
6.2 Maintenance of cells ............................................................................. 75 
6.3 MTT cytotoxicity studies ....................................................................... 75 
6.4 Glucose-stimulated insulin secretion .................................................... 75 
6.5 RIA for insulin ....................................................................................... 76 
6.5 Oxygen consumption studies ............................................................... 79 
6.6 Experiments for RT-PCR ...................................................................... 80 
6.7 Experiments for western blot analysis .................................................. 81 
6.8 Statistical analysis ................................................................................ 81 
Chapter 7: Results ....................................................................................... 82 
7.1 MTT cytotoxicity ................................................................................... 82 
 vi 
7.2 Insulin secretion studies ....................................................................... 83 
7.2.1 Chronic insulin levels ..................................................................... 83 
7.2.2 Basal insulin secretion ................................................................... 83 
7.2.3 Glucose-stimulated insulin secretion ............................................. 84 
7.2.4 Insulin content ................................................................................ 85 
7.2.5 Stimulatory index ........................................................................... 86 
7.3 Oxygen consumption studies ............................................................... 87 
7.4 RT-PCR studies ................................................................................... 88 
7.4.1 Glut-2 ............................................................................................. 88 
7.4.2 Insulin ............................................................................................ 88 
7.5 Western blot analysis ........................................................................... 89 
INS 1 .......................................................................................................... 89 
Chapter 8: Discussion of insulin secretion results ................................... 90 
Chapter 9: Conclusions and future research ............................................ 96 
REFERENCES .............................................................................................. 97 
Appendix A ................................................................................................. 107 
 
  
 vii 
Abstract 
Type 2 diabetes mellitus results from a combination of insulin resistance and 
impaired insulin secretion. The aim of this study is to investigate the effect of 
endogenous and exogenous cannabinoids on insulin resistant cell lines, viz skeletal 
muscle (C2C12) and fat (3T3-L1), and to investigate the effects of these 
cannabinoids on insulin secretion in pancreatic β-cells (INS 1).  
 
Insulin resistance was induced in the cells using 20 ng/mL TNF-α (3T3-L1) and 100 
nM insulin (C2C12). Insulin resistant cells were exposed to cannabinoids for 48 hours 
after which glucose uptake, RT-PCR and Western blot analysis was performed. 
Additionally, adipokine assays were performed on the 3T3-L1 cells. The insulin 
resistant 3T3-L1 and C2C12 cells had reduced glucose uptake, decreased IRS-1 and 
Glut-4 expression indicative of an insulin resistant state. The extract and THC 
significantly enhanced glucose uptake, IRS-1 and Glut-4 in 3T3-L1 and C2C12 cells. 
The extract and THC thus have the potential to be an insulin sensitizing agent. 
Interleukin-6 was significantly decreased by THC. 
 
INS 1 cells, cultured under normoglycemic conditions, were exposed to cannabinoids 
for 48 hours after which glucose-stimulated insulin secretion, radioimmunoassay, 
oxygen consumption, RT-PCR and Western blot analysis was performed. Insulin 
stimulatory index was not significantly affected after cannabinoid exposure, except by 
THC. The cannabinoids decreased insulin content, in a concentration dependent 
manner, but the inhibition mechanism remains elusive. The cannabinoid Treated 
cells showed insulin gene expression levels similar to the control, while only THC 
proved effective in significantly stimulating Glut-2 gene expression. Oxygen 
consumption studies showed levels lower than the control cells. 
 
Most of the cannabinoids inhibited insulin secretion under normoglycemia except 
THC, while the cannabinoids exhibited the potential to improve insulin resistant 
adipocyte and myocytes response to glucose and gene regulation.  
 
Keywords: anandamide, cannabinoids, insulin resistance, insulin secretion, THC, 
rimonabant, 3T3-L1, C2C12, INS-1 
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Chapter 1: Introduction 
Type 2 insulin-resistant diabetes mellitus accounts for 90–95% of all diabetes. 
It is a heterogeneous disorder affecting approximately 6% of the adult 
population in westernized society; its worldwide occurrence is expected to 
continue to increase by 6% yearly, possibly reaching a total of 200–300 
million cases in 2010. The main driving force behind this increasing incidence 
is the staggering increase in obesity, which is an important contributor to the 
pathogenesis of diabetes (Moller, 2001). 
1.1 Metabolic syndrome and some of its components 
The metabolic syndrome (MetS) is characterized by clustering of 
cardiovascular risk factors such as abdominal obesity, hypertriglyceridemia, 
low-serum high-density lipoprotein (HDL) cholesterol, elevated blood 
pressure, glucose intolerance, and a prothrombotic and proinflammatory state 
(Eckel et al., 2005). Insulin resistance can be seen as the link between the 
various disorders of this syndrome. People with MetS are at a greater risk of 
developing various illnesses that affect their morbidity and mortality, including 
cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) (Arai et 
al., 2008).  
 
Diabetes mellitus is a major public health burden worldwide. T2DM results 
from the inability of the body to respond correctly to the action of insulin 
produced by the pancreas (Chan et al., 2007). T2DM results from a 
combination of insulin resistance and impaired insulin secretion. These two 
disorders are interlinked, but in most individuals the onset of insulin resistance 
precedes marked β-cell dysfunction and is thought to arise from genetic 
predisposition (Nandi et al., 2004). 
The occurrence of obesity is increasing dramatically to epidemic proportions 
in virtually all populations of the world and with it comes the pathological 
consequences of T2DM and CVD as well as other less common pathologies 
(Pilch and Bergenhem, 2006). The link between T2DM and obesity is well 
established and this link is based on the ability of obesity to cause insulin 
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resistance. Insulin resistance occurs in the liver, adipose tissue and skeletal 
muscle. Defects in insulin receptor (IR) function, IR-signal transduction, 
glucose transport and phosphorylation, glycogen synthesis, glucose oxidation 
and dysregulation of fatty acid metabolism contribute to insulin resistance. 
Insulin resistance in obesity and T2DM is manifested by decreased insulin-
stimulated glucose transport and metabolism in adipocytes and skeletal 
muscle and by impaired suppression of hepatic glucose output (Kahn and 
Flier, 2000). Impaired insulin signaling in all three target tissues and, in 
adipocytes, specifically from downregulation of the major insulin responsive 
glucose transporter 4 (Glut-4), may contribute to the aforementioned 
functional defects (Durbin, 2004). 
Hyperinsulinemia appears to be a compensatory mechanism that responds to 
increased levels of circulating glucose. People who develop T2DM usually 
pass through the phases of excessive obesity; nuclear peroxisome proliferator 
activated receptor (PPAR) modulation, insulin resistance, hyperinsulinemia, 
pancreatic β-cell stress and damage, leading to gradual decrease of insulin 
secretion and increased fasting glucose levels. Fasting glucose in normal 
individuals should remain normal as long as insulin hypersecretion can 
compensate for insulin resistance. The decrease in insulin secretion leading 
to hyperglycemia occurs as a late incident and separates the patients with 
metabolic syndrome from those with or without overt diabetes (Tenenbaum et 
al., 2003).  
The possible mechanisms of early β-cell failure include mitochondrial 
dysfunction, oxidative stress, endoplasmic reticulum stress, dysfunctional 
triglyceride/FFA (TG/FFA) cycling, and glucolipotoxicity. Once hyperglycemia 
has developed, additional processes linked to glucotoxicity and the diabetic 
state, such as islet inflammation, O-linked glycosylation, and amyloid 
deposition, accelerate β-cell demise, resulting in severe β-cell phenotypic 
alterations and loss of β-cell mass by apoptosis (Prentki and Nolan, 2006). 
With insulin resistance and obesity, insulin levels increase to maintain normal 
glucose tolerance. Insulin secretion rates are three to four times higher in 
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obese insulin resistant subjects than in lean subjects. The response of the β-
cell to glucose during insulin resistance has been studied by administering 
graded intravenous glucose infusions to insulin-sensitive and insulin-resistant 
subjects with normal glucose tolerance. Insulin levels and insulin secretion 
rates were found to have increased in insulin-resistant subjects relative to 
insulin sensitive subjects (Cavaghan et al., 2000).  
Regulation of the β-cell mass appears to involve a balance of β-cell replication 
and apoptosis, as well as development of new islets from exocrine pancreatic 
ducts. Disruption of any of these pathways of β-cell formation or an increase 
in the rate of β-cell death could result in a decrease in β-cell mass. The islets 
in T2DM are characterized by deposits of amyloid, derived from the peptide 
islet amyloid polypeptide (IAPP), also known as amylin. This peptide has been 
shown to cause apoptosis of β-cells, particularly when it is in the form of small 
IAPP oligomers (Bulter et al., 2003).  
 
Figure 1.1: A model linking obesity and type 2 diabetes (Porte, 2006). 
Figure 1.1 indicates the link between T2DM, obesity and insulin resistance, 
where insulin becomes the main reason for the pairing of T2DM and obesity. 
The environment and genes interact independently with each system, at the 
defective β-cell level, the insulin resistance level, and the obesity level to 
create the multi-dimensional interactions that still need to be understood 
(Porte, 2006).  
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1.2 Insulin: Structure and secretion 
1.2.1 Structure of insulin 
Insulin is a polypeptide hormone, produced in the β-cells of the islets of 
Langerhans. It consists of two polypeptide chains, namely A and B which are 
joined by two disulfide bonds (Ganong, 1993). It is composed of 51 amino 
acid residues (figure 1.2).  
 
Figure 1.2: The amino acid sequence of human insulin, linked by disulfide bridges 
(modified from Ganong, 1993).  
Insulin's structure varies somewhat between animal species and differs 
slightly in carbohydrate metabolism control effects. Porcine insulin is close to 
the human version (Draznin and LeRoith, 1994). Insulin affects a wide variety 
of biological processes including glycogen synthesis, glucose transport, 
mitogenesis, and protein synthesis (Eldar-Finkleman and Krebs, 1997). 
1.2.2 Synthesis of insulin 
Insulin is synthesized in significant quantities only in β-cells in the pancreas. 
The insulin mRNA is translated as a single chain precursor called pre-
proinsulin, which consists of an N-terminal signal peptide linked to proinsulin. 
Removal of the signal peptide during insertion into the endoplasmic reticulum 
generates free proinsulin (Eldar-Finkleman and Krebs, 1997). Proinsulin 
consists of three domains: an amino-terminal B chain, a carboxy-terminal A 
chain and a connecting peptide in the middle known as the C peptide. Within 
the endoplasmic reticulum, proinsulin is exposed to several specific 
endopeptidases which cleave the C peptide, thereby generating the mature 
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form of insulin. Insulin and free C peptide are packaged in the Golgi into 
secretory granules which accumulate in the cytoplasm. When the β-cell is 
stimulated, insulin is secreted from the cell by exocytosis and diffuses into 
islet capillary blood (Eldar-Finkleman and Krebs, 1997).  
 
1.2.3 Insulin secretion 
Insulin is secreted primarily in response to elevated blood glucose levels 
(Tortora and Grabowski, 2003). With increasing blood glucose, glucose enters 
the β-cells via a glucose transporter (Glut-2) and is converted to glucose-6-
phosphate by glucokinase. Through the mitochondrial metabolism of glucose-
6-phosphate, ATP is generated and this results in an increase in the 
intracellular ATP/ADP ratio. Increased levels of ATP/ADP result in the K+ 
channels opening, allowing K+ to flow out. The resulting change in cell 
membrane voltage triggers the opening of membrane bound Ca2+ channels, 
allowing Ca2+ to enter the cell. Ca2+ influx, in turn, results in degranulation and 
secretion of insulin (Halvorsen and Levine, 2001). This is the main 
mechanism for release of insulin and regulation of insulin synthesis. 
 
Additionally, some insulin synthesis and release takes place generally with 
food intake, not just glucose or carbohydrate intake, and the β-cells are also 
somewhat influenced by the autonomic nervous system. Substances known 
to stimulate insulin release include amino acids from ingested proteins, 
acetylcholine released from vagus nerve endings, cholecystokinin released by 
enteroendocrine cells of intestinal mucosa and glucose-dependent 
insulinotropic peptide (GIP)(Draznin and LeRoith,1994). Three amino acids 
(alanine, glycine and arginine) act similarly to glucose by altering the β-cell's 
membrane potential. Acetylcholine triggers insulin release through 
phospholipase C, while the latter acts via adenylate cyclase (Draznin and 
LeRoith, 1994). 
Even during digestion, generally one or two hours following a meal, insulin 
release from the pancreas is not continuous, but oscillates with a period of 3–
6 minutes, changing from generating a blood insulin concentration more than 
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800 pmol/L to less than 100 pmol/L. The continual release of insulin is thought 
to avoid downregulation of insulin receptors in target cells and to aid the liver 
in extracting insulin from the blood (Hellman et al., 2007). 
Glut-2 is the major glucose transporter in β-cells and hepatocytes. It mediates 
the facilitated diffusion of glucose across the cell membranes, and initiating 
intracellular glucose metabolism via the glucose-phosphorylating enzyme, 
hexokinase (HK) IV or glucokinase. In the β-cell, the rate of glucose 
metabolism controls insulin secretion, whereas in the liver, glucose 
metabolism and transport are essential to subsequent glycogen synthesis and 
gluconeogenesis (Wu et al., 1998). 
 
When the glucose level decreases below the usual physiological value (<6.1 
mmol/L), insulin release from the β-cells slows or stops. If blood glucose 
levels drop lower than the norm, especially to dangerously low levels, release 
of hyperglycemic hormone, e.g. glucagon, occur from the α-cells of the Islet of 
Langerhans, causing the release of glucose into the blood from cellular 
stores, primarily hepatocytes. By increasing blood glucose, the hyperglycemic 
hormones correct potential life-threatening hypoglycemia. Release of insulin is 
strongly inhibited by the stress hormone norepinephrine and glucocorticoids 
(cortisol), which leads to increased blood glucose levels during stress 
(Draznin and LeRoith, 1994). 
Once an insulin molecule has docked onto the receptor and performed its 
action, it can either be released back into the extracellular environment or 
degraded by the cell. Degradation usually involves endocytosis of the insulin-
receptor complex followed by the action of insulin degrading enzyme. Most 
insulin molecules are degraded by liver cells (Duckworth et al., 1998). 
1.3 Insulin signaling 
Insulin action is mediated through the IR, a transmembrane glycoprotein with 
intrinsic protein tyrosine kinase activity. The level of tyrosine kinase activity 
reflects the serum concentration of insulin and appears to mediate the insulin 
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response through tyrosine phosphorylation of the receptor itself and 
substrates like insulin receptor substrate-1 (IRS-l) (Whites and Kahn, 1994). 
The insulin signaling pathway consists of a complex array of protein kinases 
and protein phosphatases that regulate insulin action (figure 1.3). IRS-1 and 
IRS-2 are docking proteins that are essential in initiating the pleotropic effects 
of insulin through PI3K (del Aguila et al., 1999).  
 
Insulin binds to the extracellular α subunits of its receptor. The IR consists of 
two α and two β subunits and activates the intracellular tyrosine kinase in the 
transmembrane β subunits (Tritos and Mantozoros, 1998). The activated 
insulin receptor kinase phoshorylates several cytosolic scaffold proteins which 
serves as substrates for the activated insulin receptor. With respect to glucose 
uptake, the four members of the IRS family (IRS-1, IRS-2, IRS-3 and IRS-4), 
undergo tyrosine phosphorylation in response to insulin stimulation (Panunti et 
al., 2004). 
The autophosphorylation of the insulin receptor and subsequent tyrosine 
phosphorylation of important intracellular signaling intermediates follow, 
including  IRS-1 and -2, src homology 2 (SH2)-containing protein (Shc), and 
Grb2-associated binder 1 (Gab1) (Tritos and Mantozoros, 1998). These 
activated intermediates bind to and activate other signaling molecules, 
including the adapter proteins Grb2 and Nck, the tyrosine phosphatase Syp 
(SH2 protein tyrosine phosphatase), and PI3K, amplifying and diversifying the 
initial signal generated by insulin binding to its receptor. 
The major pathways of IR signaling are through activation of the PI3K 
pathway (figure 1.4). This pathway controls the metabolic actions of insulin. In 
the PI3K pathway, insulin stimulation causes tyrosine phosphorylation of IRS 
scaffold proteins. This phosphorylation promotes the association and 
activation of PI3K. The subsequent production of phosphatidylinositol 3, 4, 5-
trisphosphate [PtdIns (3, 4, 5)P3] results in the recruitment and activation of 
phosphoinositide-dependent kinase 1 (PDK1), which phosphorylates and 
activates both λ and ζ isoforms of atypical protein kinase C (aPKC) and 
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protein kinase B (PKB), also known as Akt. Together these signaling 
cascades mobilize Glut-4 storage compartments (Watson and Pessin, 2006).  
The PI3K pathway signals an increase in protein synthesis through the 
promotion of translation and may also be responsible for the net 
dephosphorylation of key enzymes in the liver, adipose, and muscle which 
promote the formation of glycogen and triglycerides (Gibson and Harris, 
2002). 
 
PKB mediates the effects of insulin on glucose transport, glycogen synthesis, 
protein synthesis, lipogenesis and suppression of hepatic gluconeogenesis. 
PKB regulates both glucose uptake via facilitated glucose transporters, and 
intracellular glucose metabolism in insulin sensitive tissues such as skeletal 
muscle. Under non-stimulated conditions, PKB is found in the cytoplasm and 
stimulation with insulin results in translocation of PKB to the plasma 
membrane, where PKB may bind to PIP-2 and PIP-3. At the plasma 
membrane, PKB co-localizes with PDK and becomes activated by 
phosphorylation of its two principal regulatory sites, Thr308 and Ser473. 
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Figure 1.3: Insulin-signaling pathway in muscle/fat cells (Lanner et al., 2008). After 
insulin binding to its receptor, a series of signaling reactions initiate translocation of Glut-4 
containing vesicles to the cell surface. Simultaneously, extracellular Ca
2+
 enters the cell, 
resulting in localized increases that facilitate docking/fusion/insertion of Glut-4 in the 
membrane, where it accelerates glucose transport. Single arrow reflects a direct effect. 
Multiple arrows in a pathway reflect two or more steps. IRS, insulin receptor substrate; PI3K, 
phosphoinositol 3-kinase; PKB, protein kinase B; PDK1, phosphoinositide-dependent kinase 
1; GLUT 4, glucose transporter 4; PKCλζ, protein kinase C λ and ζ isoforms; CAP, Cbl 
associated protein. 
Phosphorylation of both sites is essential for the activation of PKB. PDK1 is 
the kinase phosphorylating Thr308, while the mechanism of phosphorylation 
of the Ser473 residue is unclarified. Following activation, PKB detaches from 
the plasma membrane to affect metabolic processes. Parts of the activated 
PKB translocate through the cytoplasm into the nucleus by an unknown 
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mechanism to affect gene expression. Substrates for direct phosphorylation 
by PKB include the glycogen synthase kinase-3 (GSK-3) and members of the 
forkhead box protein (Foxo)-family of transcription factors which play a critical 
role in insulin-dependent regulation of glucose homeostasis (Schinner et al., 
2005). 
 
After the second messengers for insulin action have been generated, the 
glucose transport system is activated and a large intracellular pool of glucose 
transporters is translocated to the plasma membrane. There are five major 
glucose transporters, all with distinctive tissue distribution and HK 
associations. Glut-4 is found in muscle and adipocytes, and is associated with 
HK-II. Its expression is regulated by insulin (Panunti et al., 2004). 
1.3.1 Inhibition of insulin signaling 
The duration and extent of insulin signaling is regulated at multiple levels. 
Some of the control mechanisms are set into motion directly after insulin 
stimulation occurs. These mechanisms act to terminate insulin’s effects 
through activation of lipid or protein phosphatases and through the induction 
of Ser/Thr kinases that phosphorylate and uncouple various elements along 
the insulin signaling pathways. Other negative feedback control mechanisms 
operate on a longer time scale, and involve a reduction in the cellular content 
of the IR, its substrates and other signaling elements (Zick, 2004). 
 
Termination of the insulin signal is critical for the maintenance of metabolic 
control. For example, mice lacking the protein-tyrosine-phosphatase 1B 
(PTP1B) gene exhibit increased insulin sensitivity and fail to develop insulin 
resistance under a high-fat diet. In addition, the inhibition of PTP1B-activity by 
systemic application of antisense oligonucleotides specific for PTP1B 
improved insulin sensitivity and glycaemic control in diabetic mice. Other 
phosphatases important for the termination of insulin signaling include 
phosphatase and tensin homologue (PTEN) which inactivates the lipid 
products of PI3K and SHIP2, an inositol 5 phosphatase. 
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Figure 1.4: PI3K pathway (Modified from Gibson and Harris, 2002). Insulin stimulation 
causes tyrosine phosphorylation of IRS (insulin receptor substrate) scaffold proteins 
promoting the association and activation of PI3K. The subsequent production of 
phosphatidylinositol 3, 4, 5-trisphosphate [PtdIns (3, 4, 5) P3] results in the recruitment and 
activation of phosphoinositide-dependent kinase 1 (PDK1), which phosphorylates and 
activates both λ and ζ isoforms of atypical protein kinase C (aPKC) and protein kinase B 
(PKB). 
Knockout mice with a homozygous deletion of the SHIP2 gene displayed 
increased insulin sensitivity and hypoglycaemia because of an inhibition of 
hepatic glucose production. Antisense oligonucleotides specific for PTEN 
drastically improved glycaemic control in diabetic ob/ob- and db/db-mice 
(Schinner et al., 2005). 
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Figure 1.5: The impact of Ser/Thr phosphorylation of IRS on insulin action (Zick, 2004). 
Phosphorylation of IRS proteins by kinases (mTOR, JNK, PKCζ and IKKβ) is part of a 
negative feedback control mechanism induced by insulin that results in the termination of 
insulin signal. Activation of either the same or other Ser/Thr kinases that phosphorylate the 
IRS protein, inducers of insulin resistance can inhibit their function, terminate insulin action. 
pY, phospho-Tyr; pS, phospho-Ser. 
Ser/Thr phosphorylation of IRS protein can either promote or terminate 
insulin’s signal. Ser residues at the PTB domain of IRS-1 function as positive 
effectors of insulin signaling by protecting IRS proteins from the action of 
PTPs (Zick, 2004). Other insulin-stimulated Ser/Thr kinases, including mTOR, 
c-Jun N-terminal kinase (JNK), PKCζ and inhibitor kB kinases (IKK)β,  these 
mediate phosphorylation of IRS proteins. The phosphorylation of IRS proteins 
by these kinases form part of a negative feedback control mechanism, 
induced by insulin that terminates the insulin signal. Inducers of insulin 
resistance take advantage of this negative-feedback control mechanism 
(figure 1.5) by activating Ser/Thr kinases that phosphorylate the IRS proteins, 
inhibit their function, terminate insulin action and induce insulin resistance 
(Zick, 2004). 
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1.4 Factors contributing to insulin resistance 
1.4.1 Tumor necrosis factor-α 
Tumor necrosis factor-α (TNF-α) is recognised as an insulin resistance-
inducing agent and its expression is increased in the adipose tissue of several 
animal models of obesity (Pirola et al., 2004). Direct exposure of isolated cells 
to TNF-α inhibits insulin signaling and induces a state of insulin resistance in 
3T3-L1 cells and human primary adipocytes by affecting IRS proteins. The 
mechanisms affecting IRS involve proteasome-mediated degradation, 
phosphatase-mediated dephosphorylation, and Ser phosphorylation of IRS-1, 
which converts IRS-1 to a form that inhibits IR Tyr kinase activity (Lozrenzo et 
al., 2008). Both ERK and JNK have been suggested as mediators of TNF-α 
Ser-Thr phosphorylation of IRS-1 in white adipocytes, with the Ser307 residue 
being identified as the site for TNF-α phosphorylation of IRS-1. With regards 
to this, disruption of JNK1 decreases the incidence of insulin resistance 
associated with dietary obesity. In addition, ERK and p38MAPK could inhibit 
insulin signaling by TNF-α at the level of IRS-1 and IRS-2 in 3T3-L1 
adipocytes, whereas JNK could mediate the feedback inhibitory effect of 
insulin (Lorenzo et al., 2008). Refer to section 1.7.1 for TNF-α’s role as a 
cytokine. 
1.4.2 Hyperinsulinaemia 
Hyperinsulinaemia is another factor that intensifies the insulin resistant state. 
IRS-1 protein content is reduced in 3T3-L1 adipocytes chronically exposed to 
insulin as well as in adipocytes from insulin resistant subjects and patients 
with overt T2DM (Pirola et al., 2004). Downstream of IRS-1 and -2, other 
insulin signaling molecules are deregulated by hyperinsulinaemia. PKB 
activation was reduced in adipose tissue and skeletal muscle from diabetic 
db/db mice and Glut-4 expression is lower in insulin resistant individuals. 
Thus, hyperinsulinaemia-induced deterioration of insulin action occurs at 
numerous sites along the insulin signaling pathway (Pirola et al., 2004).  
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1.5 Gene markers of insulin resistance 
1.5.1 Insulin Receptor 1 and 2 
Animal models have shown that gene disruption of IRS-1, the large docking 
protein for PI3K activation, leads to marked insulin resistance (Carvalho et al., 
2001). They reported that human fat cells from T2DM subjects have a marked 
reduction in IRS-1 protein expression and that IRS-2 then becomes the 
primary docking protein for PI3K activation in these cells. They investigated 
whether a low IRS-1 expression is related to other cellular abnormalities in 
insulin’s signaling cascade and action. Their results showed that these cells 
exhibit a pattern of abnormalities that is typical for cells from subjects with 
T2DM, including impaired insulin-stimulated activation of PI3K and PKB as 
well as low insulin-stimulated glucose transport and Glut-4 expression 
(Carvalho et al., 2001). 
IRS-1 and IRS-2 each contain multiple Ser/Thr kinases. These can be 
stimulated by TNF–α and prolonged stimulation can lead to insulin resistance 
through a decrease in the insulin stimulated tyrosine phosphorylation of the 
insulin receptor and IRS proteins (Hemi et al., 2002).  It has been thought that 
IRS-2 provides alternative pathways to compensate for impaired IRS-1 in IRS-
1-deficient mice but studies suggests that IRS-2 does not provide alternative 
insulin signaling to overcome the downregulation of IRS-1 by TNF-α (del 
Aguila et al., 1999). 
1.5.2 Glucose Transporter 4 
Glut-4 mRNA expression was quantified under treatment of TNF-α. When 
determined 4 days after initiation of exposure to TNF-α the transcription of 
both the Glut-4 and CCAAT/enhancer binding protein-α (C/EBP-α) genes was 
markedly suppressed, resulting in an 85-90% percent decrease in the mRNA 
content of these genes and a total loss of Glut-4 and C/EBP-α from the cell 
(Stephens and Pekala,1992). Changes in Glut-4 gene expression are 
observed in physiological states of altered glucose homeostasis and vary in a 
tissue-specific manner, occurring much more rapidly in adipose tissue than 
skeletal muscle. In general, Glut-4 mRNA expression is down-regulated in 
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states of relative insulin deficiency such as streptozotocin-induced diabetes 
and chronic fasting. Chronic fasting markedly reduces Glut-4 mRNA levels in 
adipose tissue (Charron et al., 1999).  
Differentiated murine 3T3-L1 and F442A adipocytes express relatively high 
levels of Glut-4 mRNA and protein similar to that found in primary isolated 
adipocytes or adipose tissue (Charron et al., 1999). The appearance of Glut-4 
mRNA in these cells first occurs about 4 days after the onset of differentiation. 
Unlike primary adipocytes or adipose tissue, 3T3-L1 adipocytes express high 
levels of the Glut-1 glucose transporter isoform (Charron et al., 1999). 
Animals chronically treated with insulin show increased Glut-4 mRNA in 
adipose tissue whereas chronic insulin treatment of 3T3-L1 adipocytes has 
resulted in either no change or in a marked reduction in Glut-4 mRNA levels. 
The different responses of Glut-4 mRNA to chronic insulin treatment in vivo 
and in vitro suggest Glut-4 mRNA does not respond directly to insulin action 
on adipose tissue. On the other hand, incubation of 3T3-L1 adipocytes in 
glucose-free medium down-regulates Glut-4 mRNA about 10-fold and is 
accompanied by the up-regulation of Glut-1 mRNA (Charron et al., 1999). 
Treatment of cells with concentrations of TNF-α as low as 0.2 nM resulted in 
repression of Glut-4 gene transcription and decreased Glut-4 mRNA stability 
(Qi and Pekala, 2000). 
1.6 Adipokines 
The discovery in the mid 1990s that adipose tissue releases specific proteins 
into the bloodstream was a breakthrough in the field of obesity and metabolic 
diseases. Among various cell types that compose adipose tissue, adipocytes 
themselves produce two major proteins: leptin and adiponectin. Adipose 
production is the principal, if not exclusive, contributor to circulating levels of 
both molecules. By acting on peripheral target tissues through specific 
receptors, leptin and adiponectin qualify as hormones (Guerre-Millo, 2008). 
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Some adipokines play a major role in insulin resistance (figure 1.6) and 
cardiovascular complications associated with obesity, especially central or 
visceral obesity. Circulating levels of serum amyloid A (SAA) are associated 
with insulin resistance in obesity and T2DM. Vaspin is a member of the serine 
protease-inhibitor family and is strongly expressed in visceral adipose tissue 
and is stimulated in mouse and human obesity (Antuna-Puente et al., 2008). 
 
1.6.1 Adiponectin 
Adiponectin is a 30kDa protein highly expressed in adipose tissue. Its plasma 
levels are between 5–30 mg/L in lean subjects and represent 0.01% of 
plasma proteins. It is present in the bloodstream in three main forms; viz a 
trimer; hexamer; and a high molecular weight (HMW) form (Antuna-Puente et 
al., 2008). Adiponectin monomers have an amino-terminal collagen-like 
domain and a carboxy-terminal globular domain that generate trimers, 
hexamers and HMW multimers.  
 
The three multimeric forms of adiponectin are found in the circulation, 
associated with several serum proteins recently characterized in humans. The 
adiponectin globular head is detected in the trimeric form in human and 
mouse plasmas, although at low concentrations. It has not yet been clearly 
established which adiponectin form(s) is (are) biologically active however, 
based on clinical observations, the HMW form is deemed the more clinically 
relevant (Guerre-Millo, 2008). 
 
Adiponectin mRNA expression varies according to tissue site, being lower in 
visceral than in subcutaneous tissue. Unlike other adipokines, adiponectin is 
under-expressed in obese patients with insulin resistance or T2DM, and in 
patients with coronary heart disease. Like leptin, adiponectin enhances insulin 
sensitivity through activation of 5’-AMP-activated kinase (AMPK) (Antuna-
Puente et al., 2008). 
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Figure 1.6: Adipose tissue, adipokines and insulin resistance (Antuna-Puente et al., 
2008). SAA, Serum amyloid A; PAI-1, plasminogen activator inhibitor; CRP. C-reactive 
protein; RBP4, Retinol-binding protein-4. 
The plasma concentration of adiponectin is lower in obese than in non-obese 
subjects. Adiponectin affects hepatic glucose production by decreasing the 
mRNA expression of two essential genes encoding gluconeogenesis 
enzymes: phosphoenolpyruvate carboxykinase; and glucose-6-phosphatase 
(Antuna-Puente et al., 2008). In obese subjects and patients with T2DM, apart 
from lower plasma adiponectin concentration, adiponectin receptor expression 
is also reduced. Thus in these patients, significant reduction of adiponectin 
sensitivity might occur. However, this is a reversible phenomenon (Więcek et 
al., 2007). 
 
In addition to its effects on insulin sensitivity, adiponectin has a vascular-
protective effect early in the atherogenesis process by interfering with the 
regulation of adhesion molecule expression on vascular endothelial cells and 
the transformation of macrophages into foam cells, and by modulating smooth 
muscle cell proliferation. Adiponectin reduces the inflammatory response 
induced by TNF-α, as shown by in vitro studies where macrophage activity 
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and TNF-α production were diminished in macrophages treated with 
adiponectin (Antuna-Puente et al., 2008).  
 
Another metabolic action of adiponectin is the capacity of its globular head to 
restrict the rise of plasma free-fatty acids following a high-fat meal in mice, by 
stimulating fatty-acid oxidation in muscles. Enhanced lipid catabolism, leading 
to reduced tissue triglyceride contents and improved insulin sensitivity was 
confirmed in insulin resistant mice receiving adiponectin (Guerre-Millo, 2008).  
 
The other well-established metabolic effect of adiponectin is to lower hepatic-
glucose production, demonstrated in response to acute adiponectin 
administration in mice and to cultured hepatocytes. This function is 
corroborated by the phenotype of adiponectin-deficient mice, which have 
higher rates of endogenous glucose production than wildtype mice during 
euglycaemic-insulin clamping. In patients with T2DM or non-alcoholic fatty 
liver disease, an inverse relationship between plasma adiponectin and 
endogenous glucose production was reported, which supports an adiponectin 
role in negatively controlling hepatic-glucose output (Guerre-Millo, 2008). 
 
The metabolic effects of adiponectin (figure 1.7) share similarity to those 
caused by activation of the AMPK in liver and muscles, indicating that 
adiponectin could act through the stimulation of this enzyme. A series of 
experimental findings showed that AMPK inactivation precludes adiponectin 
stimulation of fatty-acid oxidation in muscles and inhibition of gluconeogenesis 
in liver. Recently, adiponectin was shown to increase mitochondrial numbers 
and function in skeletal muscles through an AMPK-dependent mechanism 
(Guerre-Millo, 2008). The capacity to modulate AMPK activity is shared by a 
number of endogenous (nutrients, hormones) and exogenous (TZD, 
metformin) molecules.  
 
The genes encoding the adiponectin receptors AdipoR1 and AdipoR2 have 
been cloned. These genes are located in chromosomes 1q32 and 12p13, 
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respectively. AdipoR1 has a ubiquitous expression with a higher proportion in 
muscle, whereas AdipoR2 is predominantly expressed in liver. Recently, 
AdipoR1 and AdipoR2 overexpression or knockout animal models have 
indicated that both proteins serve as the predominant receptors for 
adiponectin in vivo, and play important roles in the regulation of lipid and 
glucose metabolism, inflammation and oxidative stress (Antuna-Puente et al., 
2008).   
 
Figure 1.7: Schematic representation of adiponectin regulation and currently known 
mechanisms of metabolic and vascular effects (Guerre-Millo, 2008). ROS: reactive-
oxygen species; n-3 PUFA: n-3 polyunsaturated fatty acids; TZD: thiazolidinediones; NO: 
nitric oxide; APPL1: a pleckstrin homology domain-containing adaptor protein; AMPK: 5’-
AMP-activated kinase; CB1: cannabinoid-1 receptor. 
Adiponectin administration had been shown to improve insulin sensitivity by 
three different groups using various rodent models. The beneficial effects of 
adiponectin administration in rodents occur through several mechanisms: 
adiponectin activates glucose utilization by muscle; induces muscle and 
hepatic fatty acid oxidation, leading to decreased triglyceride content; and 
21 
  
decreases hepatic glucose production. Few studies have been devoted to 
humans. The in vitro stimulatory effects of adiponectin on insulin-stimulated 
glucose uptake and fatty acid oxidation is impaired in skeletal muscle strips 
taken from obese subjects and type 2 diabetics (Lafontan and Viguerie, 
2006). 
 
1.6.2 Leptin 
Leptin is expressed and produced by white adipose tissue, in particular, by 
differentiated adipocytes. Subcutaneous fat is responsible of 80% of total 
leptin production. This was shown in cultures ex vivo where the production of 
leptin was higher in subcutaneous adipocytes than in those of deeper origin 
(Antuna-Puente et al., 2008.) It is a 16 kDa, 167-amino acid peptide encoded 
by the obese gene and shares the tertiary structure similar to IL-6 cytokine 
family (Zhuo et al., 2008). 
 
Plasma leptin concentration and mRNA expression in adipose tissue  are 
directly related to the severity of obesity, as an increase of fat mass is related 
with an increase of leptin, thus making leptin an indicator of total fat mass 
(Antuna-Puente et al., 2008). In contrast to adiponectin, leptin levels directly 
correlate with insulin resistance, obesity, and several CVD risk factors. Leptin 
levels have been associated with CVD beyond body mass index (BMI) in 
some but not all studies (Qasim et al., 2008).  
 
The principal biological effect of leptin in the central nervous system is the 
control of food intake and energy expenditure (Antuna-Puente et al., 2008). 
Leptin signals the amount of fat stores to the brain and is the main hormone of 
the tonic homeostatic regulatory system of energy balance. Leptin acts on the 
arcuate nucleus in the hypothalamus with the intention of reducing hunger 
and increasing energy expenditure. Arcuate nucleus neurons are known to be 
responsive to a wide array of hormones and nutrients, including leptin, insulin, 
gonadal steroids and glucose. The arcuate is a potent site of leptin action, 
mediating a component of leptin's effects via arcuate neuropeptide Y/agouti-
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related peptide and pro-opiomelanocortin neurons(POMC), and implicating 
this structure in the long-term control of energy stores (Cone et al., 2001). 
 
Elevated leptin levels in obesity are associated with a failure of endogenous 
leptin to exert its normal effects, either through a reduced transport of leptin 
into the brain, or reduced expression of the leptin receptor (ObR) in the 
arcuate nucleus. A further possibility is an increase in the concentration of 
SOCS3, which suppresses leptin signaling through the inhibition of leptin-
induced signal transducer and activator of transcription (STAT) activation 
(Stocker and Cawthorne, 2008). 
 
Six isoforms of leptin receptors have been identified; these differ in the length 
of the intracellular tail but share the same extracellular binding domain. The 
long isoform is responsible for most of the known effects of leptin mediated 
via its intracellular tail. Leptin signaling operates, with some cell-type-
dependent specificity, through different pathways involving Janus kinase 
(JAK) and STAT, mitogen-activated protein kinase (MAPK), PI3K and AMPK 
(Lafontan and Viguerie, 2006). 
 
Leptin transport across the blood–brain barrier is mediated by the ObRa 
isoform of the leptin receptor. The arcuate nucleus of the hypothalamus is a 
major site of leptin action (figure 1.8).  
 
Leptin administration reduces lipid accumulation in liver and skeletal muscle 
of lipodystrophic patients. Treatment of leptin-deficient patients with leptin 
reduces morbid obesity and reduces T2DM and hypogonadism. As with 
rodents, leptin increases fatty acid oxidation in skeletal muscle from lean, but 
not obese humans (Lafontan and Viguerie, 2006). Leptin resistance is often 
observed in obese patients. 
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Figure 1.8: Schematic representation showing leptin action (Stocker and Cawthorne, 
2008). Leptin is produced by adipose, gut and placenta and is also present in breast milk. 
Transport across the blood–brain barrier is mediated by the ObRa isoform of the leptin 
receptor. Leptin interacts with the long form of the leptin receptor ObRb. Interaction of leptin 
with its receptor involves phosphorylation of JAK2 followed by phosphorylation of tyrosine 
residues (pY-985 and pY-1138) in the receptor itself, leading to recruitment of the 
transcription factor STAT3. This is followed by transcriptional activation leading to an increase 
in satiety pathways [increasing pro-opiomelanocortin (POMC)] and a decrease in orexigenic 
pathways [decreasing neuropeptide Y (NPY)]. Sympathetic nervous system (SNS) activation 
also occurs. SOCS-3 inhibits receptor activation and transcription of the SOCS-3 gene is 
increased by leptin itself, thereby providing a feedback loop to attenuate further leptin action. 
1.7 Cytokines 
Inflammatory cytokines have metabolic actions that contribute to the 
adaptation of the organism during infectious or inflammatory stress (Tsigos et 
al., 1997). IL-6 together with TNF-α and IL-1, takes part in the inflammatory 
cascade. Elevated levels of cytokines such as IL-6, IL-1, and TNF-α and 
hormones such as growth hormone and insulin have been linked to insulin 
resistance (Senn et al., 2003). The production of these cytokines is increased 
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in obese people. This increased synthesis may interfere with the action of 
insulin to suppress lipolysis, which would represent insulin resistance of 
adipose tissue (Grundy, 2005).  
1.7.1 Tumor necrosis factor-α 
TNF-α is encoded by a signal-copy gene, which gives rise to a protein of 26 
kDa. The protein is synthesized and processed as a membrane-associated 
protein that after proteolytic cleavage is released into circulation as a 
homotrimer of approximately 51kDa (Qi and Pekala, 2000). TNF-α is a 
proinflammatory cytokine produced by numerous cells, but mainly 
macrophages and lymphocytes. Adipocytes also produce TNF-α in rodents, 
and in low quantities in humans. In rodents, TNF-α is involved in the 
pathophysiology of insulin resistance (Antuna-Puente et al., 2008).  
 One of the possible mechanisms by which this cytokine interferes with insulin 
sensitivity is through abnormal phosphorylation of IRS-1. Its expression is 
slightly modified in human obesity, and the absence of its production in 
subcutaneous adipose tissue in obese and lean men has been demonstrated 
by direct arteriovenous balance measures. This indicates that adipose tissue 
is poorly or indirectly involved in the increased circulating concentrations of 
TNF-α seen in obesity (Antuna-Puente et al., 2008).  
TNF-α is also expressed in human muscle and is found at higher levels in 
muscle of insulin-resistant and diabetic patients relative to normal lean control 
subjects. A reduction of TNF-α activity, using a chimeric antibody or as occurs 
in transgenic animals lacking either TNF-α or TNF-α receptor, improves 
sensitivity to insulin in obese animals. Although the mechanism of action of 
TNF-α in these insulin-related effects is not fully understood, it is known that a 
major component involves TNF-α inhibition of upstream insulin signaling 
(Rosenzweig et al., 2002). In this regard, a number of studies have shown that 
TNF-α both reduces insulin-stimulated tyrosine phosphorylation of IR and 
IRS-1 and inhibits tyrosine phosphorylation and activity of PI3K. 
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1.7.2 Interleukin-6 
Interleukin (IL)-6 is a cytokine produced by several cells (fibroblasts, 
endothelial cells, monocytes) and by adipose tissue, which is increased in 
obesity. In the absence of an acute inflammatory process, approximately 15–
30% of circulating IL-6 is from adipose tissue. The ability to secrete IL-6 is 
higher in visceral than in subcutaneous adipose tissue. However, adipose 
tissue is composed of numerous cells other than adipocytes, and most of the 
IL-6 comes from the stromal vascular fraction, composed of endothelial cells 
and monocytes/macrophages (Antuna-Puente et al., 2008). IL-6 is a 
multifunctional cytokine that targets several tissues and cell types (Senn et al., 
2003). The IL-6 receptor belongs to the class I family of cytokine receptors, 
which uses JAKs as intracellular signaling pathways. Studies have 
demonstrated an interaction between cytokines and insulin signaling 
pathways leading to decreased insulin signaling in the presence of cytokines.  
Members of the SOCS family associate with the IR, and their ectopic 
expression inhibits IR signaling. Several SOCS proteins are induced by IL-6; it 
is thought that IL-6 dependent insulin resistance is mediated partially by 
induction of SOCS protein(s) in insulin target cells (Senn et al., 2003).  This 
cytokine has also been shown to be elevated in the blood circulation of T2DM 
and to correlate most closely with insulin resistance. A two- to threefold 
elevation of circulating IL-6 has been observed in these conditions (Senn et 
al., 2003). 
Visceral adipose tissue produces three times more IL-6 than subcutaneous 
adipose tissue does. This may explain, in part, the deleterious role of central 
obesity in cardiovascular diseases. Indeed, visceral adipose tissue production 
of IL-6 could have a direct effect on hepatic metabolism as its venous 
drainage goes directly to the liver through the portal vein. Thus, IL-6 produced 
by intra-abdominal adipose tissue could directly contribute to visceral obesity-
related hypertriglyceridaemia by stimulating hepatic secretion of triglycerides 
[very low-density lipoprotein (VLDL)] (Antuna-Puente et al., 2008).  Adipose 
tissue IL-6 expression is increased in obesity and is a strong predictor of 
abnormalities in adipocyte and systemic metabolism (Trujillo et al., 2004). 
26 
  
Circulating and adipose tissue levels of IL-6 are chronically elevated in the 
obese and correlate with increased fasting triglycerides, plasma FFA levels, 
and systemic insulin resistance in humans (Trujillo et al., 2004). 
1.8 Cannabis 
The cannabis plant (Cannabis sativa) contains many compounds, with ∆-9 
tetrahydrocannabinol (THC) being the main psychoactive ingredient. THC 
(figure 1.9) breaks down to produce cannabinol and was identified with 
cannabidiol in the 1940s (Baker et al., 2003). THC is concentrated in the 
flowering head of the female plant and selective growing in the past 5–10 
years has substantially increased THC content from 1–3% in the 
“flowerpower” era to 6–13% and above. Cannabis may contain over 60 
cannabinoid compounds and some, such as cannabidiol, may modulate the 
response to THC (Baker et al., 2003). 
 
Figure 1.9: Chemical structure of THC (Baker et al., 2003). 
1.8.1 Cannabinoid Receptors 
Endocannabinoids are novel lipid signalers whose effects are carried out by 
CB1 and CB2 receptors. CB1 receptors are associated mainly with neurons 
and CB2 receptors are distributed among immune cells where they attenuate 
inflammatory responses to tissue injury. Both types of receptors are G protein- 
coupled receptors (GPCR) and their mediated effects are sensitive to the G 
protein blocker, pertussis toxin (PTX). Both receptors are potent regulators of 
calcium channels in neurons and secretory cells where they affect stimulus–
secretion coupling (Juan-Pico et al., 2006). 
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CB1 is negatively coupled to adenylate cyclase and may be negatively or 
positively associated with selective ion channels. CB1 is expressed strongly in 
the basal ganglia, cerebellum, and hippocampus, thus accounting for the 
effects of cannabis on motor coordination and short-term-memory processing 
(Baker et al., 2003). CB1 is expressed at high concentrations in the dorsal 
primary afferent spinal-cord regions, which are important in pain pathways, 
whereas it is expressed at low concentrations in the brainstem, which controls 
many autonomic functions. The many effects that cannabis can have are due 
to the presence of CB1 in regions that control diverse neurological functions. 
CB1 receptor has been implicated in the orexigenic effect of 
endocannabinoids through sites in the hypothalamus, limbic forebrain and 
peripheral sensory nerve terminals, as well as in the regulation of the 
metabolism, body weight and insulin resistance (Juan-Pico et al., 2006). 
 
The responsiveness of the receptor is dynamic and CB1 seems to exist in a 
partly pre-coupled state that produces different degrees of stimulation in 
different brain regions (Baker et al., 2003). Starowicz et al., (2008) have 
recently reported that the endocannabinoid system (ECS) is widely expressed 
in pancreatic islets and adipose tissue of mice and rats and certain 
components can be changed with obesity. Imaging techniques were used to 
show the CB1 receptor on α-cells (Tharp et al., 2008). 
 
CB2 is expressed primarily by leucocytes and, in contrast to CB1, is not linked 
to ion channels. CB2 has no known neurological activity but it may function in 
haemopoietic development (Baker et al., 2003).  
 
The cannabinoid system has been suggested to be involved in the regulation 
of food intake; antagonism of the CB1 receptor and deletion of CB1 receptors 
reduce food intake and body weight. It has also been demonstrated that in 
vivo CB1 receptor activation by anandamide induces glucose intolerance in 
rats and that this effect is reversed by a CB1 receptor antagonist. Thus, CB1 
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receptors may be targets for affecting islet function in diabetes. (Winzell and 
Ahrén, 2007). CB1 was visualized in glucagon-containing α-cells, while the 
CB2 receptor was found in both insulin containing β-cells and in α-cells. 
Activation of CB2 receptors by the endocannabinoids, 2-arachidonylglycerol 
(2-AG) and anandamide (AEA) in β-cells provoked a decrease of the 
amplitude of glucose-induced calcium oscillations and a reduction of insulin 
secretion. The decrease of glucose-induced insulin secretion through CB2 
receptors is a new component involved in the orexigenic action of 
endocannabinoids (Juan-Pico et al., 2006). 
 
1.8.2 Endocannabinoids 
The discovery of cannabinoid receptors suggested the existence of 
endogenous ligands capable of activating them. These are known as 
endocannabinoids, of which the best studied are N-
arachidonoylethanolamines; AEA and 2-AG (Matias and Di Marzo, 2007) 
(figure 1.10). Other endocannabinoids include: noladin ether, virodhamine (O-
arachidonoylethanolamine), narchidonoyldopamine (NADA), and 
docosatetraenylethanolamide (DEA) which have been found in the CNS. 
These compounds have cannabinoid receptor binding activity, but their exact 
physiological roles are unknown (Baker et al., 2003). 
 
AEA and 2-AG are produced on demand from membrane associated 
precursors by distinct biochemical pathways involving phospholipases D and 
C. The endocannabinoids bind and stimulate the CB receptors. AEA and 
NADA can weakly stimulate vanilloid receptors (VR1), which are heat-gated, 
non-selective ion channels associated with hyperalgesia and account for 
some non-CB mediated effects of anandamide on vascular beds (Matias and 
Di Marzo, 2007; Baker et al., 2003). 
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Figure 1.10: Chemical structure of AEA and 2-AG (Matias and Di Marzo, 2007). 
There is also a degradation system (figure 1.11) that involves re-uptake into 
the cell by diffusion-facilitated endocannabinoid selective transporters and 
hydrolysis by fatty-acid-amide hydrolase for AEA and 2-AG or a 
monoacylglycerol lipase for 2-AG. Noladin ether is degraded by acylation. 
Fatty-acid-amide hydrolase is expressed strongly in the liver, is postsynaptic 
to CB1, and is involved in degradation of oleamide, an endogenous sleep-
inducing compound related to endocannabinoids. This degrades anandamide 
to arachidonic acid and ethanolamide, which do not have CB1 binding activity 
(Baker et al., 2003). 
 
1.8.3 Endocannabinoid System 
Among the signaling systems that are thought to play a role in the control of 
energy homeostasis and endocrine functions, the ECS is one of the most 
recently discovered in the past two decades. The ECS comprises of the two 
cannabinoid receptors, CB1 and CB2; their endogenous ligands, and the 
enzymes responsible for the formation of AEA and 2-AG and for their 
degradation, which have been identified not only in neurons, but also in 
peripheral cells including white adipocytes, rat insulinoma cells and mouse 
endocrine pancreas (Matias et al., 2008). 
 
The ECS has been shown to play a fundamental role in regulating metabolism 
and body composition by enhancing the central orexigenic drive and 
increasing peripheral lipogenesis. Control of food intake and body 
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composition is the result of a series of complex interactions between the 
adipocytes, the mesolimbic system, the hypothalamus, and the 
gastrointestinal tract (Vettor et al., 2007). 
 
Figure 1.11: Endocannabinoid degradation pathway (Baker et al., 2003). 
Endocannabinoids are formed within neurons and other cell types via multiple biosynthetic 
pathways (1). Rather than being stored as active molecules these are synthesized “on 
demand” from membranous fatty-acid precursors via the activity of phosphodiesterase (PDE) 
enzymes such as phospholipase D (anandamide) and phospholipase C (2-AG). This process 
occurs (2) after cellular stimulation by signals such as neuronal depolarisation (Ca
2+
 influx) to 
cause the extracellular release of active endocannabinoids (3). After release, the 
endocannabinoid can either bind cannabinoid receptors (agonism pathway) or be degraded. 
After receptor binding (4) the receptor signals the second messenger systems (reducing 
adenylate cyclase and for CB1 inhibiting Ca
2+
 channels or stimulating inwardly rectifying K
+
 
channels) that signal the cannabimimetic activities (5). There is also a degradation pathway 
expressed on either receptor bearing or other cells. The endocannabinoids are degraded 
through reuptake by a diffusion facilitated transport molecule (6) and then hydrolytically 
cleaved by enzymes (7) such as fatty-acid-amide hydrolase to break down the 
endocannabinoids to molecules such as arachidonic acid and ethanolamine.  
 
This control was suggested by the observation that genetic and/or chronic 
pharmacological blocking of cannabinoid CB1 receptors causes inhibition of 
food intake and reduction of body weight to a higher extent than that expected 
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from the inhibitory effect on energy intake. Thus CB1 blockade normalizes 
several dysregulated metabolic parameters such as low high-density-
lipoprotein (HDL) cholesterol, high triglycerides, low adiponectin, high glucose 
and insulin, etc., in obese animals and patients in a manner partially 
independent from weight loss, thus suggesting the existence of direct effects 
of ECS in tissues and cells controlling energy homeostasis such as 
adipocytes, pancreatic islets, hepatocytes and skeletal muscle, which all 
express CB1 receptors (Matias et al., 2008). 
 
In adipocytes, endocannabinoids and CB1 receptor levels increase during 
differentiation, and CB1 stimulation leads to faster differentiation of pre-
adipocytes, stimulation of lipoprotein lipase activity, up-regulation of glucose 
uptake, inhibition of AMPK and stimulation of fatty acid synthase (Matias et 
al., 2008). These lipogenic actions of CB1 in adipocytes explain in part why 
CB1 knock-out mice fed with the same amount of food as wild-type mice still 
exhibit less fat mass. 
 
The role of the ECS in the endocrine pancreas still requires unraveling. In β-
cells from isolated mouse pancreatic islets, both CB1 and CB2 stimulation 
have been reported to inhibit insulin release, whereas in insulinoma cells 
grown in a high glucose concentration, CB1, but not CB2, stimulation causes 
enhancement of glucose-induced insulin release in human β-cells, despite the 
relatively low abundance of CB1 receptors, their stimulation also enhances 
insulin release (Matias et al., 2008; Juan-Pico et al., 2006). 
 
It is important to note that most of the peripheral effects of cannabinoids are 
reported in rodents and in cell lines while the role of the ECS in humans has 
been investigated to a lesser degree. Endogenous cannabinoids are 
increased both in subcutaneous and visceral adipose tissue of obese patients 
and in diet-induced obese mice. However, no direct evidence has been 
reported so far on the direct effects of endocannabinoids on glucose and lipid 
metabolism and on adiponectin release in human fat cells (Vettor et al., 2007). 
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1.8.4 CB1 receptor antagonist 
Rimonabant (figure 1.12) was the first CB1-receptor blocker described in 
1994. It displays a 1000-fold greater affinity for the CB1 than for the CB2 
receptor and blocks calcium and potassium channels. The drug is 
metabolised in the liver and excreted in bile (Vettor et al., 2007). 
 
 
Figure 1.12: Chemical structure of rimonabant (Matias and Di Marzo, 2007). 
Rimonabant treatment induces a dose-dependent reduction in food intake in 
various rodent models and this effect seems to be centrally and peripherally 
mediated. Potential peripheral mechanisms include enhanced thermogenesis 
via increased oxygen consumption in skeletal muscle, diminished hepatic and 
adipocyte lipogenesis, augmentation of adiponectin concentrations, promotion 
of vagally mediated cholecystokin-induced satiety, inhibition of preadipocyte 
proliferation, and increased adipocyte maturation without lipid accumulation. 
Rimonabant was also shown to increase both adiponectin gene expression in 
the adipocytes and adiponectin plasma levels (Vettor et al., 2007).   
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Chapter 2: Aim 
The aim of this study is to investigate the effect of endogenous and 
exogenous cannabinoids on insulin resistant cell lines, viz skeletal muscle 
(C2C12) and fat (3T3-L1), and to investigate the effects of these cannabinoids 
on insulin secretion in pancreatic β-cells (INS1). The cannabinoids used in 
subsequent experiments were: an organic cannabis extract, THC, 
anandamide and rimonabant.  
2.1 Objectives 
 To determine the cytotoxic effect of these cannabinoids on various 
cells lines. 
 To induce insulin resistance in fat and skeletal cell lines. 
 To determine the effect of the cannabinoids on glucose uptake in these 
cell lines. 
 To determine the effect of these cannabinoids on cytokine secretion. 
 To determine the effect of cannabinoid exposure on glucose stimulated 
insulin secretion in INS1 cells using radio immunoassay (RIA). 
 To determine the effect of cannabinoid exposure on oxygen 
consumption in the various cell lines. 
 To determine the effect of the cannabinoids on the expression of 
glucose transporters, insulin receptors using RT-PCR. 
 To determine the cell signaling mechanism activated by these 
cannabinoids in muscle and fat cells. 
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Chapter 3: Methods and Materials 
3.1 Extraction and quantification of THC in extract 
3.1.1 Chloroform extract procedure 
Cannabis (whole plant matter, leaves and seeds) was obtained from the 
South African Police Service in Port Elizabeth. A chloroform extract was 
prepared by following the cannabinoid extraction procedure described by 
Turner and Mahlberg (1984). Ten grams of dried cannabis was ground with a 
mortar and pestle. Chloroform (10 mL) was added and allowed to react for 3 
hours. The extract was then filtered using Millex Millipore filters (0.45µm) and 
the filtrate evaporated under a gentle stream of nitrogen. The remaining resin 
was resuspended in 2mL of methanol and stored under vacuum at 4˚C in a 
light protected container. 
3.1.2 HPLC Quantification THC in the organic extract 
Commercial THC (Industrial Analytical, Johannesburg, RSA) was used as a 
standard, to quantify the concentration of the THC in the extract. This was 
determined using Reverse-Phase High Performance Liquid Chromatography 
(RP-HPLC) using a C18 Grace Vydac analytical column (4.6 × 250mm, 5μm). 
The column was eluted with a mixture of acetonitrile (HPLC grade) and 0.01M 
phosphate buffer at a ratio of 70:30, respectively, using a flow rate of 1 
mL/min. The absorbance was read at 214 nm and data analyzed using the 
System Gold software. Standard THC (1 mg/mL) was diluted using a mixture 
of acetonitrile and 0.01M phosphate buffer as indicated above, to set up a 
standard curve ranging between 12.5 and 200 µg/mL (figure 3.1). THC peaks 
were identified using the retention time and the peak area was used to 
determine the concentration of the THC in the extract (Turner and Mahlberg, 
1984).  
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Figure 3.1: THC standard curve. Error bars indicate SEM (n=3) (R
2
 =0.962). 
The THC content as calculated from figure 3.1 was 1544.4 µg/mL. 
3.2 Maintenance of cells lines 
3T3-L1 preadipocytes were maintained in DMEM medium (Sigma) 
supplemented with 10% fetal bovine serum (FBS). C2C12 mouse skeletal 
myoblasts were maintained in RPMI-1640 medium (Sigma) supplemented 
with 10% FBS. During routine maintenance, cells were incubated in 10 cm 
culture dishes at 37°C in a humidified incubator with 5% CO2. Cells were 
subcultured when they were between 70-80% confluent. Before being 
trypsinized, the medium was aspirated off the cells and the cells were washed 
twice with 5 mL phosphate buffered saline (PBS). The cells were then 
covered with 1 mL trypsin (0.25% w/v) (Roche Biochemicals) which was 
aspirated off after 10 seconds, leaving approximately 100 μL in the culture 
dish. The dish was then incubated at 37°C for 10 minutes with shaking after 5 
minutes. Media with 10% FBS was used to resuspend the cells after 
incubation with trypsin (Celis, 1998).   
3.3 MTT Cytotoxicity studies 
To ascertain if any of the cannabinoids used in subsequent experiments were 
cytotoxic to any of the cell lines, MTT assays were performed on each of the 
cell lines to determine cell viability. The MTT assay (Sigma) uses the 
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cleavage of yellow tetrazolium salt (MTT) which forms water-insoluble dark 
blue crystals to determine cell numbers. Living cells are able to cleave the dye 
using their mitochondrial succinate dehydrogenase enzyme and converting it 
into the blue crystals. Absorbance, measured at 540 nm, correlates to the 
concentration of the converted dye which is proportional to the number of 
metabolically active cells in the culture (Celis, 1998). 
Cells were seeded in 24 well plates (Nunc) at densities of 25 000 and 35 000 
cells/mL for the C2C12 and 3T3-L1 respectively. After attaching overnight, the 
culture medium was replaced with medium containing the organic extract and 
cannabinoids at a range of concentrations. A 125-1000 ng and 1-10 µg/mL 
range of cannabinoids was used. Cells were incubated for 48 hours at 37°C 
after which the MTT assay was performed. 
After the 48 hour exposure to cannabinoids, the culture medium was replaced 
with fresh media containing 0.5 mg/mL MTT. Cells were incubated at 37°C for 
a 3 hour period after which the medium was removed via aspiration. DMSO (1 
mL) was added to each well and the plate was agitated at low speed for 2 
minutes before measuring the absorbance at 540 nm.  
A standard curve was constructed with cell numbers ranging between 0-
150000 cells/mL (figure 3.2). 
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Figure 3.2: MTT standard curve of cells. (a) 3T3-L1, (b) C2C12 cells. Error bars indicate 
SEM (n=3), R
2
= 0.962 and 0.961 for 3T3-L1 and C2C12, respectively. 
3.4 Glucose uptake studies 
The glucose uptake assay was performed using the GLUCOSE (Glu-cinet) kit 
(BAUER) which contains glucose oxidase and peroxidase. Glucose oxidase 
catalyzes the conversion of glucose to gluconic acid and hydrogen peroxide is 
also formed. The peroxidase then catalyzes a reaction whereby the hydrogen 
peroxide reacts with a reduced dye, 4-aminoantipyrine, which is present in the 
reagent to produce oxidized dye and water. The reduced form of dye is 
colourless while the oxidized form has a reddish colour. The coloured 
compound is then measured spectrophotometrically at A492nm (Keston, 1956). 
Control cells were represented by untreated differentiated adipocytes and 
myoblasts (NCC) incubated in culture media. Positive control cells (PCC) 
were represented by untreated differentiated adipocytes and myoblasts 
treated with 1μM metformin in culture media during the glucose uptake 
procedure. Experimental cells were represented by differentiated adipocytes 
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and myoblasts treated with either cannabis extract containing THC, THC 
standard, anandamide or rimonabant, at various concentrations. 
3T3-L1 preadipocytes were counted and seeded at a density of 35 000 
cells/mL and differentiated over a period of 3 days with a modified protocol 
using DMEM containing 10% FBS, 500 µM 3-isobutyl-1-methylxanthine 
(IBMX), 5 nM insulin and 100 nM dexamethasone (Hemati et al., 1997). After 
differentiation, the culture medium was changed and cells were incubated with 
cannabinoids for 48 hours. The C2C12 myoblasts were seeded at a density of 
25 000 cells/mL and allowed to reach confluence over a 48 hour period, after 
which they were exposed to the cannabinoids. The concentration range, as 
determined by the MTT studies, was the same for both cell lines. With the 
exception of THC standard, the nanogram concentration range of 
cannabinoids was used. A 1-10 µg/mL range of THC standard was used. 
 After the 48 hour exposure to the various cannabinoids, a glucose uptake 
assay was performed. Cells were incubated for one hour in glucose-free 
media followed by 1 hour incubation in culture medium containing 8mM 
glucose in the presence of 60 µU/mL insulin for an additional hour. 
Subsequent to exposure, 50 µl aliquots of the media were taken from the 
respective wells and added to 150 µl distilled water to achieve a four times 
dilution. The diluted aliquot (50 µl)  was added to 200 µl Glu-cinet reagent and 
incubated for 15 minutes at 37°C; thereafter absorbance was measured at 
492nm. Cells were normalized using the MTT assay (section 3.3) subsequent 
to the 8mM glucose exposure.  
 A glucose standard curve was constructed using glucose concentrations 
ranging between 0.25 and 2 mM. All standard curve concentrations were 
represented by triplicate values (figure 3.3). 
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Figure 3.3: Glucose standard curve. Error bars indicate SEM (n=3) (R
2
=0.980). 
3.5 Inducing insulin resistance 
3.5.1 Insulin resistance in 3T3-L1 cells 
Cells were counted and seeded at a density of 35 000 cells/mL and 
differentiated over a period of 3 days with a modified protocol using DMEM 
containing 10% FBS, 500 µM IBMX, 5 nM insulin and 100 nM dexamethasone 
(Hemati et al., 1997). After differentiation, the culture medium was changed 
and cells were incubated with 20 ng/mL TNF-α for a period of 24 hours to 
induce insulin resistance. 
3.5.2 Insulin resistance in C2C12 cells 
Cells were counted and seeded at a density of 25 000 cells/mL and allowed to 
reach confluence over a 48 hour period. After the 48 hour period the cell 
culture medium was changed and cells incubated with 100 nM insulin for 20 
hours (Fang et al., 2005). 
3.5.3 In vitro studies using insulin resistant 3T3-L1 and C2C12 cells 
Insulin resistant cells (IRC) where then exposed for 48 hours to cannabinoid 
concentrations ranging from 1-10 µg/mL or 125-1000 ng/mL. Thereafter 
glucose uptake was determined (section 3.4) and the cell number was 
normalized using the MTT assay (section 3.3). 
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A single concentration of each of the cannabinoids, which promoted the 
highest glucose uptake in the 3T3-L1 and C2C12 cells were then used in 
subsequent experiments (Table 3.1). 
Table 3.1: Cannabinoid concentrations used in subsequent experiments as determined 
by glucose uptake. 
Treatment (µg/mL) 3T3-L1 C2C12 
ORGANIC EXTRACT  0.5 0.5 
THC STANDARD  5 5 
ANANDAMIDE  0.75 0.25 
RIMONABANT  1 0.5 
3.6 Adipokine secretion studies 
The multiplex assay kit (Linco Research) was used for the simultaneous 
quantification of mouse adipokines: Leptin, Resistin, Adiponectin, IL-6 and 
TNF-α. It combines the principle of a sandwich immunoassay with the 
Luminex fluorescent-bead-based technology (www.lincoresearch.com/ 
protocols, 2007). An immunoassay measures the levels of a substance i.e. 
cytokines, present in a sample, using the reaction of an antibody or antibodies 
to its antigen. The assay takes advantage of the specific binding of an 
antibody to its antigen. Monoclonal antibodies are used as they only bind to 
an epitope. The antibodies used have a high affinity for the antigen (www. 
lincoresearch.com/protocols, 2007).   
The 3T3-L1 preadipocytes were treated according to sections 3.5.3 and 3.4 
using the cannabinoid concentrations from table 3.1. An aliquot (1mL) of the 
media was snap frozen and stored at - 80°C until analysis. The aliquots were 
analyzed for IL-6, TNF-α. The cytokine concentrations were assayed using 
the multiplex assay procedure in table 3.2 
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 Table 3.2: Multiplex assay procedure for 3T3-L1 cells (www.Millipore.com). 
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3.7 Experiments for RT-PCR 
3.7.1 Total RNA isolation and Quantification 
RNA extraction was performed using the Qiagen RNeasy Lipid Tissue Mini Kit 
for the 3T3-L1 cells and RNeasy Mini kit for the C2C12 cells; all RNA 
molecules longer than 200 nucleotides are isolated. The procedure involved 
enrichment for mRNA since RNAs less than 200 nucleotides were selectively 
excluded (www.qiagen.com). 
RNeasy Kits integrate phenol/ guanidine-based lysis and silica gel-membrane 
purification of total RNA. QIAzol lysis reagent is a monophasic solution of 
phenol and guadine thiocyanate designed to facilitate the lysis of fatty tissues 
and inhibit RNases. A spectrophotometer was used to quantify and qualify the 
RNA. RNA (10 μl) is diluted 50 times using 10mM Tris-HCl at pH 7.5. The 
spectrophotometer is blanked using this buffer. RNA purity is determined 
using the A260nm/A280nm ratio. The A280nm reading is an indication of protein 
contamination. The concentration of the RNA can be determined from the 
A260nm since an absorbance of 1 unit at 260nm corresponds to 44μg of RNA 
per mL (Sambrook and Russel, 2001). 
RNA extraction was performed in 10 cm culture dishes. Cells were treated as 
in section 3.5.3 and glucose uptake performed as in section 3.4. The RNA 
extraction procedure for the 3T3-L1 cells was a modified method to that of the 
C2C12 cells due to the fat content in the 3T3-L1 cells. To lyse the cells, 1mL 
Qiazol lysis reagent was added directly to the culture dish and transferred to 
an eppendorf which was incubated at room temperature (Rt) for 5 min. 
Chloroform (200µl) was then added and the eppendorf was shaken for 15 
seconds, and incubated at Rt for 2-3 minutes. Thereafter the samples were 
centrifuged (13.4 x g) at 4° C for 15 min. The upper aqueous phase was 
transferred to a new collection tube. For the C2C12 cells 600 µl of buffer RLT 
was added to lyse the cells before transferring them to a collection tube. The 
procedure was then the same for both cell lines. An equal volume of 70% 
ethanol was added to the lysate and after mixing 700 µl of the sample was 
transferred to an RNeasy spin column and centrifuged for 15 seconds. This 
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was repeated until all the sample was passed through the column. In order to 
wash the spin column, 700 µl of buffer RW1 was then added to the column 
and centrifuged (13.4 x g) for 15 seconds. After each step, the flow-through 
was discarded. RPE buffer (500µl) was then added to the spin columns and 
centrifuged (13.4 x g) for 15 seconds and then a second aliquot of 500 µl was 
added and centrifuged (13.4 x g) for 2 minutes. The RNeasy spin column was 
then placed in a new collection tube and 30 µl of RNase free water was 
applied directly to the spin column and centrifuged (13.4 x g) for 1 minute. The 
elute was then reapplied to the spin column and centrifuged (13.4 x g) for a 
further 1 minute to yield the RNA.  A 10 µl aliquot was used to quantify the 
RNA spectrophotometrically and the remaining RNA was stored at -80°C for 
subsequent use in RT-PCR experiments. 
3.7.2. cDNA synthesis 
The conversion of RNA into a cDNA template is an important contributor to 
the variability and sometimes lack of reproducibility observed in RT-PCR 
experiments. Several factors need to be considered during this conversion 
process. Firstly, the dynamic state of cells contributes to inherent variation in 
RNA prepared from biological samples. Secondly, purified RNA may be of 
variable quality and, once extracted, is unstable. Thirdly, the efficiency of RNA 
to cDNA conversion is dependent on template abundance. It is significantly 
lower when target templates are rare and is negatively affected by non-
specific or background nucleic acids present in the RT reaction (Bustin et al., 
2005).  
 
Therefore cDNA was prepared using gDNA wipeout buffer, Quantiscript 
Reverse Transcriptase, Quantiscript RT Buffer, RT Primer Mix and RNase 
free water at Rt. The procedure for cDNA construction is shown in table 3.3 
and 3.4. All the cDNA samples were stored at - 80º C until used in RT-PCR. 
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Table 3.3: Genomic DNA Elimination Reaction Components (www.qiagen.co.za). 
Component Volume/ Reaction 
gDNA wipeout buffer 4 µl 
Template RNA 2 µg 
RNase – free water Variable 
Total Volume 28 µl 
 
Table 3.4: Reverse Transcription Reaction Components (www.qiagen.co.za). 
Component Volume / Reaction 
Reverse Transcription mastermix 
Quantiscript Reverse Transcriptase 2 µl 
Quantiscript RT Buffer, 5x 8 µl 
RT Primer mix 2 µl 
Template RNA Variable 
Entire genomic DNA elimination reaction (Table 3.3) 28 µl 
Total Volume 40 µl 
 
3.7.3 RT- PCR 
A two step RT-PCR procedure was followed as it allowed for multiple PCR 
reactions to be performed from one RT reaction. This allowed a greater 
degree of flexibility with primer choice and it enabled the long term storage of 
cDNA (www.qiagen.co.za). 
 SYBR Green I, is commonly used fluorescent DNA binding dye, binds all 
double–stranded DNA and detection is monitored by measuring the increase 
in fluorescence throughout the cycle. SYBR Green I has an excitation and 
emission maxima of 494 nm and 521 nm, respectively. Detection occurs 
during the extension phase of RT-PCR. The fluorescent dye allows one to 
analyze various targets without the synthesizing target-specific labeled probes 
(www.qiagen.co.za). 
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Genes of interest that were investigated include IRS-1, and Glut-4 of mouse 
origin. Primers were designed using Beacon Designer® 3 (Biorad). The 
housekeeping genes evaluated were cyclophilin A (cyclo A), ubiquitin C 
(UBC) and tyrosine-3-monooxygenase/tryptophan-5-monooxygenase-
activation protein, zeta polypeptide (Ywaz). 
 Table 3.5: Primer temperature and molarity conditions for RT-PCR. 
Gene/Protein 
name 
PCR 
temp 
(°C) 
Molarity 
(nM) 
Forward sequence Reverse sequence 
IRS-1 58 400 GCTACTCACTCTTCCTTG CACTCTGGTTATGGTTGG 
Glut-4 60 300  CCAGCCTACGCCACCATAG TTCCAGCAGCAGCAGAGC 
Cyclophilin A 58 500  TCACCATCCCGACTGTGGA AAATGCCCGCAAGTCAAAGA 
UBC 58 500  GACAGGCAAGACCATCACTC CCAAGAACAAGCACAAGAAGG 
Ywaz 58 500  GAGTGTAGTCTGTGTGGGTAC GCTGTGGTCAAGGGTGTG 
 
The RT-PCR was performed using the iQ SYBR Green Supermix (BIO-RAD) 
and the BIO-RAD iQ detection system. One can directly compare the 
threshold cycle (CT) values in a method called the comparative (ΔΔ CT) 
method (Bustin et al., 2005). This method involves comparing the CT values of 
the sample of interest with a control sample and these are normalized to a 
suitable housekeeping gene. Average CT values are obtained through 
subtracting the CT value from a housekeeping gene. In this way one 
normalizes the gene expression to determine an estimation of gene 
expression (www.qiagen.co.za). In addition, geNorm was used to determine 
the stability of the housekeeping genes and all the housekeeping genes used 
had M values less than 1.5. 
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Figure 3.4: A typical RT-PCR housekeeping standard curve using cyclophilin A as an 
example. Correlation Coefficient: 0.995 Slope:-3.213 PCR Efficiency: 104.8% y=-3.213x+ 
32.134.  
3.8 Experiments for western blot analysis 
Experiments for western blots were performed in 10 cm culture dishes. Single 
cannabinoid concentrations were used (table 3.1) and cells were treated as in 
section 3.5.3 and glucose uptake performed as in section 3.4.  Cell lysis buffer 
(1mL) (50mM Tris-HCl, pH8; 150mM NaCl; 0.02 % NaN3, 1 % Triton X-100; 
1% protease inhibitor (Sigma)) was added to the cells (Vivancos and Moreno, 
2005). Cells were then centrifuged at 12 000 x g for 10 minutes and the 
supernatant was transferred to a new collection tube and stored at -80°C. 
3.8.1 BCA assay 
The bicinchoninic acid (BCA) assay depends on the conversion of Cu2+ to Cu+ 
under alkaline conditions. The Cu+ is then detected by reaction with protein 
(Walker, 1994). The BCA assay is stable under alkali conditions, and has the 
advantage that it can be carried out as a one-step process compared to the 
two steps needed in the Lowry assay. The reaction results in the development 
of an intense purple color with an absorbance maximum at 562 nm. Since the 
production of Cu+ in this assay is a function of protein concentration and 
incubation time, the protein content of unknown samples may be determined 
spectrophotometrically by comparison with known protein standards. An 
additional advantage of the BCA assay is that it is generally more tolerant to 
the presence of compounds that interfere with the Lowry assay. In particular it 
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is not affected by a range of detergents and denaturing agents such as urea 
and guanidinium chloride, although it is more sensitive to the presence of 
reducing sugars (Walker, 1994). 
The protein content of the samples for western blot analysis was determined 
using a clear 96 well microtiter plate (Nunc) based on the BCA assay. Cell 
supernatant (10µl) was added to 200 µl BCA reagent (reagent A + reagent B 
[50:1]) and incubated at 37°C for 30 minutes. After incubation, samples were 
read at A540nm. BSA (0-20mg/mL) was used to construct a standard curve 
(figure 3.5).  
 
Figure 3.5: An example of a BSA standard curve. Error bars indicate SEM (n=3) 
(R
2
=0.997). 
3.8.2 SDS-PAGE and Protein transfer 
 Proteins (50µg) were separated on 10 % SDS gels and electrophoresed at 
100V for 90 minutes (Laemmli, 1970).   
 
After electrophoresis, the separated proteins based on their molecular mass, 
was transferred to polyvinylidene difluoride (PVDF) membranes. PVDF 
membranes are suitable for western blotting since they retain proteins under 
extreme conditions of exposure to acidic or basic conditions as well as under 
organic solvent conditions (www.biorad.com). The membranes were pre-wet 
in 100 % methanol for 1 – 2 seconds and then placed in double distilled water 
for 5 minutes to remove the methanol. The methanol allowed the hydrophobic 
surface to wet with aqueous solvents. The membrane was then equilibrated in 
transfer buffer for 30 minutes, which was made up from 25 mM Tris, 192 mM 
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glycine and 20% methanol. Two pieces of fibre pads and filter paper, per 
membrane, were cut slightly bigger than the dimensions of the gel, and were 
completely saturated with transfer buffer (4◦C). SDS-PAGE gels were allowed 
to equilibrate in transfer buffer for 30 minutes to remove electrophoresis buffer 
salts and detergents. These salts may increase the conductivity of the transfer 
buffer and the amount of heat generated during the transfer, if not removed. 
This step also ensured that the gel would not shrink during the transfer. The 
cassette holder was packed in layers in the following order: fibre pad, filter 
paper, gel, membrane, filter paper and then fibre pad. Air bubbles were 
removed and proteins were transferred for 1 hour at 250 mA 
(www.biorad.com). 
 
After transfer the membranes were washed in Tris buffered saline (TBS) (50 
mM Tris-HCl, 0.9% NaCl, pH7.4) for 5 minutes. This was repeated thrice. The 
membranes were then blocked in 2% skim milk overnight. The 2% BSA was 
made up in wash buffer TBS. After the overnight block in 2% BSA the 
membranes were briefly rinsed in TBS. The membranes were then incubated 
for 2 hours in 0.2% skim milk containing primary antibody (1:1000 dilution). 
After incubation the membranes were washed for 5 minutes in TBS (triplicate 
washes). The secondary antibody was then added and allowed to incubate for 
1 hour. Thereafter the membranes were washed in quadruplicate in TBS 
(www.biorad.com). 
 
To detect the secondary antibody the membranes were incubated for 15 
minutes in 5 mL 5-bromo-4-chloro-3-indolyl Phosphate/ Nitroblue Tetrazolium 
(BCIP/NBT) (Sigma). Images were captured using an Alpha imager 3400. The 
antibodies used are listed in table 3.6. Fold increases were calculated from 
densitometry ratios of treatments versus control or treatment versus 
treatment. 
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Table 3.6: Primary and secondary antibodies used in Insulin resistance studies. 
Primary antibody (Cell 
Signaling) 
Primary 
Dilution 
Secondary antibody (sigma) 
Secondary 
dilution 
IRS 1 mouse mAb, 
180kDa  
1:1000 
Anti-Mouse IgG Alkaline 
phosphatase conjugate 
1:30 000 
Phospho- IRS 1 mouse 
mAb, 180kDa 
1:1000 
Anti-Mouse IgG Alkaline 
phosphatase conjugate 
1:30 000 
PI3 Kinase p85 rabbit 
mAb, 85 kDa  
1:1000 
Anti-rabbit IgG Alkaline 
phosphatase conjugate 
1:30 000 
Phospho-PI3K p85 60 
and 85kDa  
1:1000 
Anti-rabbit IgG Alkaline 
phosphatase conjugate 
1:30 000 
* Supplier in brackets 
3.9 Statistical Analysis 
Error bars indicate the standard error of the mean (SEM) unless specified 
otherwise. The two-tail paired Student’s t-test was used to determine 
significance of results (p<0.05). 
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Chapter 4: Results  
4.1 MTT cytotoxic assay 
To ascertain which concentration range of each of the cannabinoids used was 
the least cytotoxic to the cell a MTT assay was performed. After 48 hour 
exposure to the cannabinoids in nanogram concentrations, cell viability was 
measured spectrophotometrically. 
 Table 4.1(a): Percentage cell viability for 3T3-L1 cells (n=4). 
Treatment (µg/mL) Extract THC ANA RIM 
0.125 81 74 92 114 
0.25 85 52 116 110 
0.5 86 48 106 93 
0.75 80 26 116 117 
1 93 99 85 118 
3 90 82 56 101 
5 65 86 47 98 
7 60 73 51 121 
10 27 82 45 125 
 
Table 4.1(b): Percentage cell viability for C2C12 cells (n=4). 
Treatment (µg/mL) Extract THC ANA RIM 
0.125 91 106 105 107 
0.25 85 90 112 137 
0.5 80 55 95 119 
0.75 82 42 88 96 
1 86 90 92 80 
3 23 80 66 75 
5 10 90 9 103 
7 7 83 8 62 
10 6 79 9 125 
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The cannabinoids had an increase in cytotoxicity with increasing 
concentration. However, the THC standard exhibited higher cytotoxicity at 
lower concentrations which were overcome at higher concentrations. This 
abnormality could be explained by variability associated with cell culture or 
possibly a poor replicate experiment. The extract, anandamide and 
rimonabant were less cytotoxic between 0.125-1 µg/mL while THC standard 
was less cytotoxic between 1-10 µg/mL for both cell lines. These 
concentration ranges were used in subsequent experiments. 
Table 4.2: A summary of the key used for subsequent experiments. 
Treatment 
(µg/mL) 
1 2 3 4 5 
Extract, ANA,RIM 0.125 0.25 0.5 0.75 1 
THC standard 1 3 5 7 10 
4.2 Glucose uptake studies 
4.2.1 Non-Insulin resistant studies 
Cells were exposed for 48 hours to cannabinoids to determine the effect of 
the cannabinoids on glucose uptake in normal cells. 
 
Figure 4.1: Glucose uptake in 3T3-L1 cells exposed to cannabinoids. Error bars 
indicate SEM (n=6). 
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As figure 4.1 shows, the 3T3-L1 cells after cannabinoid exposure did not have 
enhanced glucose uptake. None of the treatments promoted glucose uptake 
higher than that of PCC. For the extract, glucose uptake increased to 0.5 
µg/mL. At this concentration the glucose uptake is only slightly higher than the 
NCC. The THC standard at lower concentrations had an inverse effect to that 
of the extract. At 1 and 10 µg/mL, glucose uptake is increased to that of NCC. 
Anandamide and rimonabant appear to suppress glucose uptake with the 
exception of 0.5 µg/mL. At this concentration glucose uptake was equivalent 
to that of NCC. At concentrations below 0.5 µg/mL both cannabinoids appear 
to suppress glucose uptake. At 0.75 and 1 µg/mL glucose uptake appears to 
increase again but at a level lower than that induced by 0.5 µg/mL.  
In figure 4.2 the cannabinoids enhanced glucose uptake to a level similar to 
NCC in C2C12 cells. The effects of the extract remained similar to the level of 
NCC with a peak in glucose uptake at 0.5 µg/mL.  THC standard increased 
glucose uptake above the NCC with the highest glucose uptake promoted at 1 
and 5 µg/mL but not significantly. Anandamide had a concentration dependent 
increase in glucose uptake with the highest increase at 1 µg/mL. 
 
 
 
Figure 4.2: Glucose uptake in C2C12 cell exposed to cannabinoids. Error bars indicate 
SEM (n=6). 
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At 1 µg/mL, glucose uptake was enhanced to levels similar to PCC. 
Rimonabant appears to follow a similar concentration dependant increase, 
with the exception that the highest glucose uptake is promoted at 0.75 µg/mL. 
4.2.2 Insulin resistant studies 
In figure 4.3 there was a significant 5-fold decrease in glucose uptake in IRC 
compared to the PCC (p< 0.05). The extract (0.5 µg/mL) showed a significant 
4, 3 and 6-fold increase in glucose uptake when compared to NCC, PCC and 
IRC (p< 0.01) respectively. THC standard induced significantly higher glucose 
uptake than NCC, PCC and IRC at 1, 3 and 5 µg/mL of THC standard 
respectively (p< 0.01). 
Anandamide and rimonabant improved glucose uptake levels higher than that 
of IRC but not significantly higher than the NCC or the PCC. For subsequent 
experiments single concentrations of the cannabinoids were used. For the 
extract, this concentration was 0.5 µg/mL; standard THC was 5 µg/mL; 
anandamide was 0.75 µg/mL and rimonabant was 1 µg/mL. 
  
Figure 4.3: Glucose uptake in insulin resistant 3T3-L1 cells exposed to cannabinoids. 
Error bars indicate SEM (n=6).*p<0.05 IRC relative to PCC. 
#
 p<0.01 treatment relative to 
NCC, PCC and IRC. 
In the C2C12 cells there was a 3-fold decrease in glucose uptake in the IRC 
compared to PCC (p<0.05) (figure 4.4). The extract had a concentration 
dependant increase in glucose uptake, with a maximum uptake at 0.5 µg/mL. 
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THC standard enhanced glucose uptake in IRC with maximum uptake at 5 
µg/mL. Anandamide decreased glucose uptake with increasing concentration, 
with the highest glucose uptake at 0.25 µg/mL. Rimonabant was the least 
effective in promoting glucose uptake in IRC with maximum glucose uptake at 
0.25 µg/mL. None of the cannabinoids enhanced glucose significantly relative 
to the controls. The concentrations that promoted the highest glucose uptake 
were then used in subsequent experiments. 
 
Figure 4.4: Glucose uptake in insulin resistant C2C12 cells exposed to cannabinoids. 
Error bars indicate SEM (n=6). * p<0.05 IRC relative to PCC. 
4.3 Adipokine assay 
The 3T3-L1 cells were assayed for the presence of various adipokines and 
cytokines. The assay was kindly performed with the assistance of Dr Peter 
Adrian, who had the luminometer required for the assay. The samples were 
assayed for the presence of adiponectin, leptin, TNF-α and IL-6. When the 
results were analyzed it was found that for adiponectin, leptin and TNF-α the 
concentrations were too low to be extrapolated from the standard curve and 
could therefore not be represented graphically.  
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Figure 4.5: IL-6 secretions from insulin resistant 3T3-L1. Error bars indicate SEM (n=4). 
* p<0.05 treatment relative to IRC. 
IL-6 secretion was increased in the IRC when compared to the PCC. A 
decrease in IL-6 secretion was observed for all the cannabinoids treatments 
with significant reductions seen for treatments with THC standard, 
anandamide and rimonabant when compared to IRC (p<0.05). In summary 
the THC was the most effective in reducing the amount of IL-6 secreted by the 
3T3-L1 cells. 
4.4 RT-PCR studies 
The effects of cannabinoids on gene expression were investigated. Insulin 
resistant cells treated with cannabinoids were evaluated for IRS-1 and Glut-4 
expression. 
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4.4.1 IRS-1 gene expression 
 
Figure 4.6: IRS-1 gene expression in insulin resistant 3T3-L1 cells after cannabinoid 
treatment. Error bars indicate SEM (n=4). *p<0.05 IRC relative to PCC; 
#
p<0.01 
treatment relative to NCC, IRC. 
There was a 3-fold reduction in IRS-1 gene expression (fig 4.6) in IRC 
compared to PCC in the 3T3-L1 cells (p<0.05). The extract (5-fold) and THC 
standard (8-fold) both had a significant increase in IRS-1 gene expression 
compared to the IRC (p<0.01). Anandamide and rimonabant treatment 
resulted in similar levels of gene expression relative to each other, but were 
not significantly higher than NCC or IRC.  
The IRC when compared to the PCC, showed a 5-fold reduction in IRS-1 
gene expression (fig 4.7) in the C2C12 cells (p<0.01). The extract was 
significantly higher than NCC (3-fold) and IRC (5-fold) (p<0.01) but did not 
increase gene expression higher than that of PCC. 
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Figure 4.7: IRS-1 gene expression in insulin resistant C2C12 cells after cannabinoid 
treatment. Error bars indicate SEM (n=4). *p< 0.05; 
#
p<0.01. 
THC standard significantly increased gene expression when compared with 
NCC (5-fold) and IRC (8-fold) (p<0.01) but was not significantly higher than 
PCC. Anandamide and rimonabant showed increased gene expression when 
compared to NCC (2-fold) and IRC (4-fold) (p<0.05).  
4.4.2 Glut- 4 gene expression 
Glut-4 gene expression in 3T3-L1 (figure 4.8) was significantly reduced (5-
fold) in the IRC when compared to PCC (p<0.01). The extract (p<0.05) and 
THC (p<0.01) had significantly increased Glut-4 expression, 4- and 6-fold 
respectively, when compared with IRC. Anandamide had significantly 
increased Glut-4 gene expression 3-fold when compared with IRC (p<0.05) 
and rimonabant increased gene expression above that of IRC to levels similar 
to the NCC. 
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Figure 4.8: Glut-4 gene expression in insulin resistant 3T3-L1 cells after cannabinoid 
treatment. Error bars indicate SEM (n=4). *p< 0.05 treatment relative to PCC; 
#
p<0.01 
treatment relative to IRC. 
Glut-4 gene expression in C2C12 cells (figure 4.9) was significantly reduced 
(6-fold) in the IRC when compared to PCC (p<0.01). There was a marginal 
increase in gene expression in the extract compared to PCC and a significant 
increase in expression (6-fold) when compared to IRC (p<0.01). A significant 
increase was observed in the THC-treated cells when compared to NCC (4-
fold) and IRC (9-fold) (p<0.01). Anandamide showed a significant increase (4-
fold) in Glut-4 expression when compared to IRC (p<0.05). Rimonabant 
showed a marginal increase in gene expression when compared to NCC and 
IRC. 
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Figure 4.9: Glut-4 gene expression in insulin resistant C2C12 cells after cannabinoid 
treatment. Error bars indicate SEM (n=4). *p< 0.05; 
#
p<0.01. 
4.5 Western Blot analysis 
Western blots were performed on protein lysates from the cells after treatment 
with the cannabinoids to examine the effects on IRS-1, PI3K and the 
phosphorylated forms of these proteins. Densitometric analysis of the 
Western blots was performed using the Alpha Imager. Giving an arbitrary unit 
of 1 to the control samples, the relative values of the samples were 
determined. 
 
4.5.1 IRS-1 Western blot analysis 
 
  3T3-L1          
   C2C12              
Figure 4.10: A typical set of Western blot results of the various cannabinoid treatments 
with a monoclonal mouse antibody raised against IRS-1 of 3T3-L1 and C2C12 cells. The 
bands observed correspond to a molecular weight of 180 kDa. Lanes: (1) NCC, (2) PCC, 
(3) IRC, (4) Extract, (5) THC, (6) ANA and (7) RIM (n=3). 
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In the 3T3-L1 cells there was a 2-fold increase in IRS-1 in PCC when 
compared to the NCC (figure 4.10). The IRC was expressing IRS-1 but less 
than the PCC. There was a 2.4-fold protein increase in the extract and a 1.7-
fold increase THC when compared to PCC. Anandamide and rimonabant 
showed a 1- and 2-fold reduction respectively, in protein compared to the 
PCC.  
Protein expression of IRS-1 in the C2C12 was similar between the NCC and 
PCC. There was a slight (< 1-fold) reduction in protein for the IRC compared 
to the PCC. The extract and THC had approximately 3-fold increase in protein 
expression compared to the PCC. Anandamide expressed a 1.2- fold increase 
in protein compared to IRC. Rimonabant showed protein expression similar to 
that of anandamide. 
4.5.2 Phosphorylated IRS-1 Western blot analysis 
In the 3T3-L1 cells, IRC had a 1.3-fold reduction in phosphorylated IRS-1 
when compared to PCC (figure 4.11). The extract and THC treatment resulted 
in phosphorylated IRS-1 levels similar to NCC. Anandamide expressed a 2.5-
fold increase in phosphorylated IRS-1 compared to IRC. Rimonabant had 
comparable levels of phosphorylated IRS-1 to that of IRC. 
 
3T3-L1            
C2C12  
Figure 4.11: A typical set of Western blot results of the various cannabinoid treatments 
with a monoclonal mouse antibody raised against phosphor-IRS-1 of 3T3-L1 and 
C2C12 cells. The bands observed correspond to a molecular weight of 180 kDa. Lanes: 
(1) NCC, (2) PCC, (3) IRC, (4) Extract, (5) THC, (6) ANA and (7) RIM (n=3). 
In the C2C12 cells no sharp band was detected for the IRC indicating that no 
phosphorylated IRS-1 was detected (figure 4.11). The extract and THC had a  
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1.5- and 1.8-fold increase, respectively, of phosphorylated IRS-1 when 
compared to PCC. Anandamide and rimonabant increased phosphorylated 
IRS-1by 2.4- and 1.8-fold respectively, compared to PCC.  
 
4.5.3 PI3K Western blot analysis 
The NCC showed reduced PI3K in the 3T3-L1 cells while none was detected 
for the PCC (figure 4.12). The IRC had 1.6-fold higher PI3K than the NCC. 
The extract showed a 3- and 9- fold increase in PI3K compared to NCC and 
IRC, respectively. THC and anandamide had a 1.6-fold increase in PI3K 
compared to IRC. Rimonabant had PI3K levels similar to IRC. 
 
 
3T3-L1   
C2C12   
Figure 4.12: A typical set of Western blot results of the various cannabinoid treatments 
with a monoclonal mouse antibody raised against PI3K p85 in 3T3-L1 and C2C12 cells. 
The bands observed correspond to a molecular weight of 85 kDa. Lanes: (1) NCC, (2) 
PCC, (3) IRC, (4) Extract, (5) THC, (6) ANA and (7) RIM (n=3). 
In the C2C12 cells PI3K was 3-fold higher in PCC than NCC (figure 4.12). IRC 
had a 3-fold reduction PI3K compared to PCC. The extract and anandamide 
had increased PI3K compared to PCC (<1-fold). THC and rimonabant had 
PI3K similar to PCC.  
 
4.5.4 Phosphorylated PI3K Western blot analysis 
The 3T3-L1 cells showed reduced phospho-PI3K for the PCC and IRC (figure 
4.13). The extract had a 1-fold reduction in phospho-PI3K compared to NCC. 
THC and anandamide showed a 2.3-fold increase in phospho-PI3K compared 
to NCC. Rimonabant showed a reduction in phospho-PI3K expression 
compared to NCC (< 1-fold).  
1 2 3 4 5 6 7 
63 
  
In the C2C12 cells (figure 4.13) phosphorylated PI3K was similar for all 
treatments. There was no significant change in phosphorylated PI3K when 
compared to the controls. 
 
3T3-L1  
C2C12   
Figure 4:13: A typical set of Western blot results of the various cannabinoid treatments 
with a monoclonal mouse antibody raised against phospho-PI3K p85 for 3T3-L1 and 
C2C12 cells. The bands observed correspond to a molecular weight of 85 kDa. Lanes: 
(1) NCC, (2) PCC, (3) IRC, (4) Extract, (5) THC, (6) ANA and (7) RIM (n=3). 
 
  
1 2 3 4 5 6 7 
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Chapter 5: Discussion of insulin resistance results  
An increase in features of the MetS such as obesity, insulin resistance and 
dyslipidaemia, has resulted in a worldwide epidemic of T2DM (Moller, 2001). 
Insulin regulates glucose homeostasis through coordinated effects on the 
stimulation of glucose uptake in peripheral tissues and suppressing hepatic 
glucose uptake (Lorenzo et al., 2008).  
 
Glucose is the primary source of energy for the human body and blood 
glucose concentrations are regulated within a narrow range of 5–6 mM. 
Skeletal muscle and fat are major insulin-sensitive tissues and the principal 
sites of insulin-mediated glucose disposal (Lanner et al., 2008). Pretreatment 
of adipocytes with TNF-α decreased the rate of insulin-stimulated glucose 
uptake by 60% (Sartipy and Loskutoff, 2003).  
 
The ability of the ECS to modulate food intake resulted in most researchers 
focusing on the central nervous system, whereas the effect of CB1 receptor 
activation on the peripheral organs regulating metabolic processes has been 
less extensively studied. The possibility that endocannabinoids might also 
directly modulate several organs involved in metabolic functions, such as the 
adipose tissue, the skeletal muscles, the liver, the endocrine pancreas and 
the gastrointestinal tract represents a novelty in the research field (Pagotto et 
al., 2006). 
 
Reports derived from obese animals and humans identify a close association 
between the development of obesity with a simultaneous overactivation of the 
ECS. This was shown by an increased intra-tissue or haematic amount of 
endocannabinoids and by an overexpression of CB1 receptor mRNA 
expression in several peripheral tissues involved in metabolic processes 
(Matias and Di Marzo, 2007). Adipose tissue has shown more evidence 
concerning overactivation of ECS which has been demonstrated in rodents 
and in humans. In animals, an upregulation of the CB1 receptor has been 
observed in the adipose tissue of genetically obese compared with lean mice 
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and in cultured adipocytes under conditions of hyperinsulinemia (Bellocchio et 
al., 2008). 
 
Laboratory research on animals and humans has demonstrated that the 
primary psychoactive element in cannabis is Δ9-THC. THC and its metabolites 
are highly fat soluble, so they may remain in the fatty tissues of the body for 
long periods of time (Hall et al., 2003). Stimulation of appetite is one of the 
most commonly related effects of marijuana in humans and Δ9-THC has been 
reported to produce hyperphagia (Trillou et al., 2002). A major difference 
between anandamide and THC is that, unlike the long-acting plant-derived 
THC, anandamide has a shorter duration of action. Termination of 
anandamide action may be caused by its rapid metabolism to inactive 
metabolites and through uptake by a hypothesized anandamide transporter 
(Wiley et al., 2006). Insulin-mediated glucose uptake in mouse adipocytes 
was stimulated by anandamide via CB1 receptors (Gasperi et al., 2007). Four 
phase III clinical trials on the effects of rimonabant, a CB1 antagonist, have 
been published describing the reduction in body weight in obese subjects and 
reduction in cardiovascular risk factors in obese and diabetic patients caused 
by CB1 inhibition (Pagano et al., 2007). 
 
Several studies have demonstrated that TNF-α impairs insulin responsiveness 
in cultured adipocytes. Characterization of the defect caused by TNF-α has 
been vague, because the cytokine interferes with insulin signaling at multiple 
levels. Acute exposure (15–120 min) of 3T3-L1 adipocytes to TNF-α has been 
reported to enhance insulin-stimulated IRS-1 tyrosine phosphorylation and 
binding to PI3K (Guo and Donner, 1996). Additionally, several other studies 
demonstrated that acute treatment (6 h) of human or 3T3-L1 adipocytes with 
TNF-α decreased insulin-stimulated IRS-1 tyrosine phosphorylation, PI3K 
activity, and glucose transport (Liu et al., 1998; Engelman et al., 2000).  
 
Prolonged exposure to TNF-α was shown to inhibit both IR 
autophosphorylation and IRS-1 phosphorylation (Hotamisligil et al., 1994). 
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Chronic treatments also decreased transcript and protein levels of molecules 
that mediate the effects of insulin, including IRS-1, cyclic-nucleotide 
phosphodiesterase-3B (PDE3B), and Glut-4 (Stephens et al., 1997; 
Landstrom et al., 2000). Reduced amounts of these proteins resulted in 
impaired insulin responses. 
 
Hyperinsulinaemia in cell culture models has been shown to develop insulin 
resistance (Pryor et al., 2000). Insulin-stimulated tyrosine phosphorylation of 
IR and IRS-1, activation of PI3K and glucose uptake are impaired by chronic 
treatment with insulin (Kumar and Dey, 2002). This in vitro treatment allows 
direct assessment of the effect of an additional treatment on the biological 
response to insulin stimulation (Li et al., 2003).  Studies in the skeletal muscle 
from T2DM patients demonstrate impaired insulin activation of the IRS-1/PI3K 
signaling pathway to glucose transport. In addition, defective Glut-4 
translocation in the skeletal muscle may also contribute to impaired glucose 
homoeostasis in T2DM patients (Bjornholm and Zierath, 2005). Insulin 
resistance in skeletal muscle manifests primarily as a glucose transport and 
serine phosphorylation of critical sites on IRS-1 thus inhibits binding and 
activation of PI3K (Savage et al., 2005). A decreased association of PI3K with 
IRS-1 is a key defect in insulin resistance in skeletal muscle in T2DM (Cusi et 
al., 2000).  
 
Metformin reduces fasting plasma insulin and improves whole-body insulin-
stimulated glucose metabolism (Bailey and Turner, 1996). Metformin 
enhanced basal glucose uptake in insulin-resistant myotubes as well as basal 
p38 activation and is able to alleviate the defects in insulin signaling caused 
by chronic insulin treatment in rat adipocytes (Pryor et al., 2000). Metformin 
can enhance the insulin-stimulated tyrosine phosphorylation of IR and IRS-1, 
PI3K activity associated with IRS-1 at 400 mM concentration in C2C12 
myotubes thus enhancing insulin signaling in insulin resistant skeletal muscle. 
The mechanism by which metformin stimulates glucose uptake is poorly 
understood. At the cellular level, it has been shown in L6 skeletal muscle cells 
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that metformin action involves the translocation of glucose transporters from 
an intracellular pool to the plasma membrane (Hundal et al., 1992).  
 
Activation of CB1 receptor promotes glucose entry into fat cells. In human 
primary adipose cells, CB1 receptor activation stimulates glucose uptake and 
this effect is mediated by translocation of the insulin-regulated Glut-4 from the 
intracellular compartment to plasma membrane (Pagano et al., 2008). This 
cannabinoid-stimulated glucose uptake in fat cells is mediated, partially by the 
same molecular machinery that is responsible for insulin-induced glucose 
uptake, i.e., activation of PI3K. Inhibition of PI3K by wortmannin was shown to 
completely block the effect of CB1 receptor activation on glucose uptake 
(Pagano et al., 2008). 
 
Glucose entry into adipocytes is additionally mediated by a rise in intracellular 
calcium coming from the extracellular environment (Pagano et al., 2007). In 
experiments carried out with calcium-free medium or with EGTA, a calcium-
chelating agent, activation of CB1 receptor lost its effect on Glut-4 
translocation and glucose uptake. The effect of the CB1 receptor agonist on 
glucose uptake was fully blocked by rimonabant. The magnitude of the effect 
of endocannabinoids on glucose uptake was 40–50% of the effect of insulin; 
however, the physiological significance of the endocannabinoids-induced 
glucose disposal by fat cells still remains to be determined (Pagano et al., 
2008). Another target of ECS-mediated obesity may be the skeletal muscles 
in which CB1 receptor increased expression has been found in diet-induced 
obese mice (Cavuoto et al., 2007).   
 
From the effects observed on glucose uptake, the cannabinoids have varying 
effects depending on the metabolic state of the cells. In the non-insulin 
resistant 3T3-L1 cells (figure 4.1) the extract and THC standard enhanced 
glucose to levels similar to NCC. Anandamide enhanced insulin-induced 
glucose uptake at a single concentration (0.5 µg/mL). Rimonabant 
suppressed glucose uptake at concentrations lower than 0.5 µg/mL, while at 
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concentrations above this, glucose uptake is stimulated to levels similar to 
NCC.  
 
The effect of cannabinoids on glucose uptake in normal C2C12 muscle cells 
was more pronounced than in normal 3T3-L1 cells (figure 4.2). All the 
cannabinoid treatments enhanced glucose uptake similar to or higher than the 
NCC. This increase in glucose uptake is similar to the findings in literature for 
adipocytes. However, rimonabant treatment does not result in inhibition of 
glucose uptake. 
 
 When IRC cells were exposed to cannabinoids, the effects were more 
pronounced than in normal 3T3-L1 cells (figure 4.3). TNF-α significantly 
suppressed glucose uptake when compared to the NCC cells, thus indicating 
impairment in the insulin signaling mechanism. The extract (0.5 µg/mL) and 
THC (5 µg/mL) enhanced glucose uptake significantly relative to IRC, 
indicating that these compounds reversed the negative effects of TNF-α and 
brought about a positive physiological response to the stimulus. Anandamide 
and rimonabant enhanced glucose uptake compared to the IRC, and this 
effect was more pronounced in the IRC cells than in the NCC cells. The 
cannabinoids, including rimonabant, improved glucose in insulin resistant 
3T3-L1 cells. 
 
Hyperinsulinemia was used to induce insulin resistance in the C2C12 cells 
and there was a suppression of glucose uptake in the IRC (figure 4.4) relative 
to the NCC. Although the cannabinoids enhanced glucose uptake relative to 
IRC, none of the cannabinoids stimulated glucose uptake to levels similar to 
that of the NCC. This therefore indicates that the beneficial effects of the 
cannabinoids are possibly limited to normal metabolic muscle cells. However, 
the cannabinoids significantly increased glucose uptake in the IRC 3T3-L1 
cells. 
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Adiponectin is an important adipocytokine with insulin-sensitizing effects and 
could be a novel treatment target for insulin resistance and T2DM. It has been 
shown to be suppressed in states of insulin resistance and obesity 
(Fasshauer et al., 2003). TNF-α acts locally at the site of white adipose tissue 
through autocrine or paracrine mechanisms or in combination, having effects 
on insulin resistance and induction of IL-6 (Lorenzo et al., 2008). TNF-α  has 
been shown to severely suppress adiponectin expression in a dose and time 
dependent manner which possibly contributes to the impairment of insulin 
sensitivity in states of increased TNF-α levels (Fasshauer et al., 2003). 
 
IL-6 was shown to induce physiological changes suggestive of the catabolic 
state with increased plasma free fatty acids and fat oxidation and inhibition of 
adipose tissue lipoprotein lipase activity. All these effects are opposite to 
those of insulin, thus, impairing insulin action (Bastard et al., 2000). 
 
Bellocchio et al., (2008) showed that in cultured adipocytes, CB1 agonist 
activation is not able to modify the expression of IL-6 mRNA. CB1 receptor 
blockade has been demonstrated by several groups to increase adiponectin in 
white adipose tissue and 3T3-F44A adipocyte cells (Matias et al., 2007). CB1 
receptor blockade by rimonabant significantly increased adiponectin mRNA 
expression and decreased visfatin. Both apelin and IL-6 mRNAs expression 
were inhibited by rimonabant (Bellocchio et al., 2008).  From data obtained by 
various experiments in pre-adipocytes and fully mature adipocytes, it is 
thought that CB1 activation is involved in cell growth and differentiation of 
adipocytes, in modulation of adipokines secretion and in lipogenesis 
stimulation (Bellocchio et al., 2008). The inhibition of the CB1 receptor by 
rimonabant is able to interfere with those adipocyte functions, often inducing 
an inhibitory effect. This antagonist effect is particularly important in the 
presence of obesity. Vast amounts of data confirmed a close association 
between an overactivation of the ECS and obesity.  
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From the adipokine assay, the cannabinoids failed to stimulate the secretion 
of adiponectin. Leptin and TNF-α levels, however remained low (results not 
shown). The suppression of adiponectin secretion by rimonabant correlates to 
findings in literature although those results are representative of a non-insulin-
resistant state. The PCC secreted IL-6 and this IL-6 concentration was 
increased in the IRC treated with TNF-α (figure 4.5). The extract treatment 
resulted in IL-6 levels similar to PCC while THC, anandamide and rimonabant 
suppressed IL-6 levels relative to IRC. Inhibition of IL-6 secretion from the 
adipocytes by the cannabinoids is indicative of a possible protective function 
of the cannabinoids in insulin resistant 3T3-L1 cells since an elevated IL-6 
level is linked to insulin resistance and obesity. The reduction in IL-6 could 
reverse the adverse effects of IL-6 on insulin action thus improving the effects 
of insulin on glucose homeostasis. The levels of IL-6 for the NCC were far 
lower than those of the PCC. Metformin is an established treatment for T2DM 
for its insulin sensitizing effects although the mechanism of action is 
somewhat elusive. The cannabinoids although stimulating IL-6 secretion, had 
levels lower than that of metformin which could still make them suitable as 
potential insulin sensitizing agents. 
 
IRS-1 is a docking protein that needs to become phosphorylated in order to 
activate PI3K, a necessary step for the initiation of several effects of insulin 
such as glucose transport (Carvalho et al., 1999). The Ser307 residue on IRS-
1 has been shown to be a site phosphorylated by several kinases, including 
mTOR, inhibitor of kappa B kinase β (IKKβ) and c-Jun kinase (JNK) (Gual et 
al., 2005). Thus IRS-1 molecules phosphorylated on this site are capable of 
becoming tyrosine-phosphorylated in response to insulin, thus having 
decreased ability to interact with PI3K. Elevated levels of phospho (p)-Ser307-
IRS1 have been reported in animal models of insulin resistance (Werner et 
al., 2004) and the equivalent Ser312 site in human IRS1 has been shown to 
be hyperphosphorylated in insulin-resistant subjects (Morino et al., 2005). 
Phosphorylation of IRS-1 on Ser632 has also been implicated in insulin 
resistance. Since Ser/ Thr hyperphosphorylation of IRS molecules play a role 
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in the induction of insulin resistance, it is thought that inhibition of the 
molecules causing the phosphorylation may constitute a viable approach to 
the relief of insulin resistance (Bloch-Damti et al., 2006). 
 
TNF–α promotes Ser/Thr phosphorylation of IRS-1 and 2 and this 
phosphorylation of IRS-1 reduces the probability of IRS-1 associating with 
insulin receptor (Senn et al., 2003). A low IRS-1 expression was associated 
with a low Glut-4 expression and reduced insulin-stimulated glucose transport 
(Carvalho et al., 2001).  
 
In the IRC 3T3-L1 cells, TNF-α down-regulated IRS-1 expression (figure 4.6), 
IRS-1 protein (figure 4. 10) and reduced phosphorylated IRS-1 protein (figure 
4.11). Glut-4 was significantly down-regulated by TNF-α exposure (figure 4.8). 
These two features are characteristic in rodents and humans in an insulin 
resistant state in the adipocytes cells. From figure 4.12 there is a reduction in 
PI3K after TNF-α exposure. These results taken with figure 4.3 are indicative 
of an insulin resistant state in the 3T3-L1 cells induced by TNF-α exposure. 
The low TNF-α levels in the adipokine assay, could possibly improve the 
sensitivity of the fat tissue to insulin, by reducing the IRS-1 phosphorylation, 
thus improving glucose uptake in response to insulin stimulation. 
 
In muscle, hyperinsulinemia lead to decreased IR protein expression; 
decreased IRS-1 and IRS-1-associated PI3K activation (Li et al., 2000).The 
abnormality in association of PI3K with IRS-1 in insulin-resistant patients 
appears to be a significant defect that may result in decreased insulin-
stimulated glucose disposal in muscle (Cusi et al., 2000). 
 
The rate-limiting step for glucose utilization in muscle and adipose tissue is 
the transmembrane transport of glucose mediated by Glut-4, which is 
expressed primarily in skeletal muscle, heart, and adipocytes (Carvalho et al., 
2005). Glut-4 gene expression is down-regulated in adipocytes but not in 
muscle from humans with T2DM or obesity (Carvalho et al., 2001). Less is 
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known about the Glut-4 trafficking pathway and its associated molecular 
machinery in the muscle fiber in comparison with the adipocyte. Similar to the 
adipocyte, Glut-4 appears to be responsible for most or all of the insulin-
stimulated glucose transport that occurs in muscle fibers (Mueckler, 2001).  
In human adipocytes, CB1 activation resulted in stimulation of Glut-4 
translocation and increased intracellular Ca2+ availability. This effect was 
dependent on activation of PI3K, thus CB1 and insulin receptors converge on 
the same pathways with respect to glucose uptake into human adipocytes 
(Engeli, 2008). 
 
Hyperinsulinemia treatment decreased IRS-1 gene expression in C2C12 cells 
(figure 4.7). Glut-4 gene expression was also significantly down-regulated 
after hyperinsulinemia treatment (figure 4.9).  However, IRS-1 protein was not 
significantly decreased (figure 4.10) nor was IRS-1 phosphorylation 
significantly increased after treatment with high insulin (figure 4.11). PI3K 
protein expression was reduced in the IRC relative to the NCC (figure 4.12). 
The cannabinoids had a significant effect on gene expression in the 3T3-L1 
and C2C12 cells. The extract and THC significantly increased IRS-1(figure 4.6 
and 4.8) and Glut-4 (figure 4.7 and 4.9) gene expression in both cell lines, 
indicative of a positive physiological effect induced by these cannabinoids in 
IRC. The increase in IRS-1 gene expression was related to the increase in 
IRS-1 protein expression, induced by exposure to the extract and THC, in 
both the muscle and adipocyte cells (figure 4. 10). These results correlate to 
the increase in glucose uptake. 
 
In figure 4.6, IRS-1 gene expression was not significantly increased by 
anandamide or by rimonabant in the fat cells.  These cannabinoids in the 
C2C12s (figure 4.7) did significantly increase IRS-1 expression higher than 
the IRC but did not increase gene expression to levels equivalent to the PCC.  
The IRS-1 protein expression in the C2C12 and 3T3-L1 cells was not 
significantly higher for anandamide and rimonabant. Anandamide and 
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rimonabant were the only cannabinoids to show increased phosphorylation of 
IRS-1 relative to controls for both cell lines (figure 4.11). 
 
The cannabinoids had a significant effect on Glut-4 expression, with Glut-4 
being up-regulated by all the cannabinoids in both cell lines (figure 4.8 and 
4.9).  The lack of significant IRS-1 and Glut-4 contributed to the poor 
stimulation of glucose uptake by anandamide and rimonabant in the cell lines. 
 
The PI3K protein expression was significantly increased for both cell lines 
(figure 4.12) with the muscle expressing more PI3K than the fat cells. THC 
and anandamide in the 3T3-L1 cells (figure 4.13) showed increased 
expression of phosphorylated PI3K. The C2C12 cells had less phosphorylated 
PI3K protein expressed. The cannabinoids improved PI3K activation thus 
reversing the inhibitory effects induced by the insulin resistance treatments to 
possibly restore the insulin signaling cascade. 
 
The cannabinoids had positive effects on the adipocytes and muscle in their 
ability to reverse the insulin resistance effects caused by TNF-α and 
hyperinsulinemia on glucose uptake and IRS-1 and Glut-4 gene expression. 
The extract and THC performed better than anandamide and rimonabant in 
the glucose uptake and gene expression studies. Rimonabant, in obesity 
studies, had inverse effects to anandamide, however, in this insulin resistant 
study rimonabant mimicked the effects of anandamide.  
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PART 3: INSULIN SECRETION 
STUDIES 
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Chapter 6: Methods and Materials 
6.1 Extraction and quantification of THC in extract 
The THC extraction and quantification was performed as in section 3.1.1 and 
3.1.2. 
6.2 Maintenance of cells 
The pancreatic rat INS1 cells were maintained in RPMI-1640 with Glutamax 
supplemented with 10% FBS, sodium pyruvate, Hepes and β- 
mercaptoethanol (Gibco). Cells were subcultured when they reached 70% 
confluence and were split in a 1:5 ratio during routine maintenance. 
6.3 MTT cytotoxicity studies 
MTT cytotoxicity was performed as in section 3.3 with the exception of cells 
seeded at a density of 30 000 cells/mL. A standard curve was constructed 
with cell numbers ranging from 0 - 80 000 cells/mL (figure 6.1). 
 
Figure 6.1: MTT standard curve for INS1 cells.  Error bars indicate SEM (n=3) 
(R
2
=0.971). 
6.4 Glucose-stimulated insulin secretion  
To observe the effect the cannabinoids had on insulin secretion under 
hyper/hypoglycemic conditions, cells were seeded at a density of 30 000 
cells/mL in 24 well plates (Nunc) and allowed to attach for 16 hours. After 
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attachment the cell culture medium was changed and cells were incubated 
with a range of cannabinoid concentrations for 48 hours.  From the MTT 
experiments, a range of 0.25-1 µg/mL was used for the organic extract, 
anandamide and rimonabant and a 3-10 µg/mL range of THC standard was 
used. 
After 48 hours of exposure, the culture medium was transferred to 1.5 mL 
eppendorf tubes stored at -20°C (these samples were used to determine the 
chronic insulin levels).  Krebs buffer (1x), containing 3.3 mM glucose (1mL)  
was  added to each well  and incubated at 37 °C for 30 minutes.  This medium 
was aspirated from each well and discarded.   A second mL of 1x Krebs 3.3 
mM glucose solution was added to each well and incubated for 1 hour at 37 
°C. Thereafter, the media was transferred to 1.5 mL tubes and stored at -20°C 
(to be used for determining the basal insulin levels). One mL of 1x Krebs 33.3 
mM solution was added to each well and incubated at 37°C for 1 hour.  Media 
was pipetted into 1.5mL eppendorf tubes and stored at -20◦C (for 
determination of glucose-stimulated insulin levels). Finally, 1mL of 0.18M HCl 
in 70% ethanol was added, incubated for 1 hour and  transferred to 1.5mL 
eppendorf  tube and stored at  -20 °C (for determining insulin content). 
6.5 RIA for insulin 
Insulin release was evaluated after exposing the INS1 cells to 
hyper/hypoglycemic conditions (section 6.4). 
In a radioimmunoassay, a fixed concentration of labeled tracer antigen is 
incubated with a constant dilution of antiserum so that the concentration of 
antigen binding sites on the antibody is limited. When unlabeled antigen is 
added to the system, there is competition between the labeled tracer and 
unlabeled antigen for the limited and constant number of binding sites on the 
antibody. Therefore the amount of tracer bound to antibody will decrease as 
the concentration of unlabeled antigen increases. This can be measured after 
separating antibody-bound from free tracer and counting either one, or both 
fractions. A standard curve was constructed with increasing concentrations of 
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standard unlabeled antigen and from this curve the amount of antigen in 
unknown samples can be calculated. The rat insulin assay (Millipore) utilizes 
125I-labeled insulin and a rat insulin antiserum to determine the level of rat 
insulin in culture media by the double antibody/PEG technique (www. 
lincoresearch.com/protocols, 2007). This technique involves nonspecific 
protein precipitation with PEG to rapidly separate bound and unbound 
hormone through precipitation at low cost and reduced experimental time 
(Peterson and Swerdloff, 1979). 
 
Cell supernatants from section 6.4 were analyzed for insulin using the 
following protocol as outlined in table 6.1. A liquid scintillation analyser (TRI-
CARB 2300TR) was used to count the radioactivity of the precipitated 
samples. A standard curve of insulin ranging from 0.1-10 ng/mL was 
constructed (figure 6.2). 
 
 Table 6.1: The RIA protocol for standard and test sample preparation 
(www.millipore.com). 
Day 1 
 
 
 
 
 
 
 
 
Vortex, 
cover 
and 
incubate 
at 4˚C for 
24hrs 
Day 2 
Tube 
number 
Assay 
buffer 
Standards and 
samples 
[125I] 
Insulin 
tracer 
Rat 
insulin 
antibody 
Precipitating 
reagent 
1,2 - - 100 µl - - 
3,4(NSB) 200 µl - 100 µl - 1.0 mL 
5,6 (Bo) 100 µl 100μl 0.1ng/mL 100 µl 100 µl 1.0 mL 
7,8 - 100μl 0.2ng/mL 100 µl 100 µl 1.0 mL 
9,10 - 100μl 0.5ng/mL 100 µl 100 µl 1.0 mL 
11,12 - 100μl 1ng/mL 100 µl 100 µl 1.0 mL 
13,14 - 100μl 2ng/mL 100 µl 100 µl 1.0 mL 
15,16 - 100μl 5ng/mL 100 µl 100 µl 1.0 mL 
17,18 - 100μl 10ng/mL 100 µl 100 µl 1.0 mL 
19-till end - Samples 100 µl 100 µl 1.0 mL 
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After the addition of the precipitating reagent the samples were vortexed and 
incubated for 20 minutes at 4oC. The supernatant was then discarded and the 
pellet re-suspended in 1mL liquid scintillation cocktail. 
 
The average of the non-specific binding tubes (NSB), tubes 3–4, was 
subtracted from the average of each tube, except the total counts. The 
percent of tracer bound was calculated as follows: 
 
%B = {Total binding counts (tubes 5–6) ⁄ Total counts (tubes 1–2)} x 100 (%B should be in the 
range of 35–50%) 
 
The percent of total binding (% B⁄Bo) for each standard and sample was 
calculated as follows:  
% B⁄Bo = (Sample or standard ⁄ Total binding) x 100 
 
A log-log standard curve was then constructed by plotting the % B⁄Bo for each 
standard on the y – axis and the known concentrations on the x–axis. Insulin 
concentrations for samples were then calculated from the standard curve 
(Morgan and Lazarow, 1963). 
 
 
Figure 6.2: Insulin standard curve. Error bars indicate SEM (n=3) (R
2
=0.998). 
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From the RIA single cannabinoid concentrations were selected for use in 
further studies. The cannabinoid concentrations selected for INS 1 cells are 
summarized in table 6.2. 
 Table 6.2: Cannabinoid concentrations for INS 1 as determined by RIA. 
Treatment  (µg/mL) 
Extract  0.5 
THC standard  5.0 
Anandamide  0.75 
Rimonabant 1.0 
6.5 Oxygen consumption studies 
The oxygen consumption of the cells was determined using a Rank Brothers 
Oxygen Electrode, which is an electrochemical sensor for oxygen.  The 
oxygen electrode is capable of detecting oxygen in the range of 0.01 to 100%. 
Detection of the oxygen is through the use of two electrodes, a platinum and 
silver electrode which has been separated from the test medium via an 
oxygen permeable Teflon membrane.  The platinum electrode acts as a 
cathode and the silver electrode as the anode. These are connected through 
a conduction fluid of 3M potassium chloride.  When oxygen comes into 
contact with the platinum electrode it is reduced to water, the reduction 
reaction is coupled to an oxidation reaction involving the silver electrode 
connecting the silver to silver chloride.  The current produced from these 
reactions is related to the partial pressure of oxygen using formula 1: 
Id = 4.F.Pm.A.P(O2)/b.......Formula 1 
Where F = Faraday’s constant,  
Pm = oxygen permeability of the Teflon membrane  
A is the surface area of the Pt electrode, and 
b = the thickness of the Teflon membrane 
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 The test solution, 1 million cells/mL within the appropriate media, is placed 
within the incubation chamber (set at 37°C), the oxygen consumption of the 
cells is then measured and captured and data is then analyzed using Labchart 
6 software (Hitchman, 1978; Less and Tsao, 1979). 
Experiments for oxygen consumption analysis were performed in 10 cm 
culture dishes. Once cells had reached confluence they were incubated with 
the cannabinoid (Table 6.2) for 48 hours. Cells were trypsinized and counted 
using a haemocytometer and 1 million cells/mL was used for oxygen 
measurements. Fresh media was used before each measurement. Prior to 
measuring oxygen consumption the Rank brothers’ oxygen electrode, was 
calibrated using media to calibrate it as the 100% oxygen level. Cells were 
resuspended in fresh media before measuring, and measured for 500 
seconds, and then oligomycin was added and measured for an additional 200 
seconds. Oligomycin inhibits ATP synthase by blocking its proton channel, 
which is necessary for oxidative phosphorylation of ADP to ATP. 
6.6 Experiments for RT-PCR 
Cells were cultured in 10 cm culture dishes and exposed to cannabinoids 
(Table 6.2) for 48 hours. Thereafter, RT-PCR experiments were performed as 
in section 3.7.1.  Exceptions are highlighted below. An RNeasy Mini Kit 
(Qiagen) was used to extract the total RNA from the INS 1 cells using a 
method described in section 3.7.1. 
Genes of interest for the INS 1 cells were Glut-2 and insulin. The 
housekeeping genes used were cyclophilin A, β-tubulin and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) which were chosen for their ability to be 
unaffected by the experimental conditions. The geNorm analysis of the 
housekeeping genes stability corresponded with an M value of less than 1.5 
for all the housekeeping genes used. 
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Table 6.3: Primer temperature and molarity conditions for RT-PCR. 
Gene/Protein 
name 
Temperature 
(°C) 
Molarity 
(nM) 
Forward 
sequence 
Reverse 
Sequence 
Glut-2 58 500 ATGACATCAAT
GGCACAGACA
C 
GGACACAGACAGAG
ACCAGAG 
Insulin 60 500 CACCTTTGTG
GTCCTCACCT 
CCAGTTGGTAGAGG
GAGCAG 
Cyclo A 58 500 ACGTGGTCAA
GACTGAGTGG 
CGTGCTTCCCACCA
GACC 
β-tubulin 58 300 AACCCAGCCC
AGTTCTAAG 
GCGATTCCCGTGTC
TAAATG 
GAPDH 60 500 TCCTTGCCTCT
CAGACAATG 
ACTGGATGTTCCTT
CTCTTAC 
 
6.7 Experiments for western blot analysis 
Cells were cultured in 10 cm culture dishes and exposed to cannabinoids 
(Table 6.2) for 48 hours. Thereafter, procedures for western blot analysis 
were performed as in section 3.8. 
The transfer time was extended to 2 hours to ensure the most efficient 
transfer of protein to the PVDF membrane. Glut-2 (Santa Cruz Biotechnology) 
was used in a 1:200 dilution and the secondary antibody was Anti-Goat IgG 
alkaline phosphatase conjugate (Sigma) (1:30 000 dilution). 
6.8 Statistical analysis 
All results represent at least three independent experiments, with the error 
bars representing the standard error of the mean (SEM). The paired Student’s 
t-test was used to determine significance of results, with p<0.05 set as being 
significantly. 
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Chapter 7: Results  
7.1 MTT cytotoxicity 
To ascertain the potential cytotoxic effect of the compounds, MTT studies 
were performed. The results can be seen in the table below. 
Table 7.1: Percentage cell viability of INS-1 cells. 
Treatment 
(µg/mL) 
Extract THC ANA RIM 
0.125 81 65 92 114 
0.25 91 38 116 111 
0.5 81 55 106 93 
0.75 83 29 116 117 
1 97 97 85 113 
3 8 81 56 104 
5 4 84 47 85 
7 36 88 51 82 
10 5 85 45 76 
 
With the exception of the THC standard, the 0.125-1 µg/mL range had the 
highest percentage viability for the cannabinoids. At lower concentrations the 
THC was highly toxic to the cells; this could be due to the THC or variations 
within the cells during handling. THC standard was less toxic between 1-10 
µg/mL range. Based on these results, the 0.125-1 µg/mL range was used for 
the organic extract, anandamide and rimonabant and between a 1-10 µg/mL 
range was used for the THC standard. 
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 Table 7.2: A summary of the key used for subsequent experiments. 
Treatment (µg/mL) 1 2 3 4 
Extract, ANA,RIM 0.25 0.5 0.75 1 
THC standard 3 5 7 10 
7.2 Insulin secretion studies 
7.2.1 Chronic insulin levels 
The 0.25 µg/mL extract, 3 µg/mL THC standard and 0.5 µg/mL anandamide, 
stimulated insulin secretion in the chronic state (figure 7.1). At higher 
concentrations (0.5 -1 µg/mL and 3-10 µg/mL) the extract and THC inhibited 
insulin secretion significantly compared to NCC (p<0.01). Anandamide 
significantly inhibited insulin secretion at concentrations 0.25, 0.75 (p<0.01) 
and 1 µg/mL (p< 0.05). Rimonabant significantly (p<0.01) inhibits insulin 
secretion at all concentrations. 
 
Figure 7.1: Chronic insulin levels of INS-1. Error bars indicate SEM (n=6). * indicates 
p<0.05, 
#
 indicates p<0.01 for Extract, THC, ANA and RIM relative to NCC. 
7.2.2 Basal insulin secretion 
Cells were exposed to 3.3 mM glucose for an hour and the supernatant was 
analyzed for basal insulin secretion. With reduced glucose exposure one 
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expects insulin levels to be suppressed. The extract however, showed a 
concentration dependent increase in insulin secretion, with a significant 
increase at 1 µg/mL (p<0.05) compared to NCC. THC had a concentration 
dependent decrease in insulin secretion, with a significant decrease at 10 
µg/mL THC (p<0.01), compared to NCC (figure 7.2). Anandamide decreases 
insulin secretion at 0.25 and 0.5 µg/mL (p<0.01). Anandamide (1 µg/mL) 
moderately increased insulin secretion relative to NCC. Rimonabant 
increased insulin secretion significantly at 0.25 µg/mL (p<0.05) relative to 
NCC. With increasing rimonabant concentration, there was a concentration 
dependent decrease in insulin secretion. 
 
Figure 7.2: Basal insulin secretion of INS-1. Error bars indicate SEM (n=6). * p<0.05; 
#
 
p<0.01 treatment relative to NCC. 
 
7.2.3 Glucose-stimulated insulin secretion 
Cells were exposed to media containing 33.3 mM glucose, thereafter insulin 
secretion was measured. The NCC had elevated insulin levels when 
compared with basal NCC (figure 7.2 vs 7.3). There was a significant 
reduction in insulin secretion with 0.5 µg/mL extract (p<0.01) relative to NCC. 
THC decreased insulin secretion with increasing concentration, with a 
significant difference at 10 µg/mL, compared to NCC (p<0.01). Anandamide 
showed a concentration dependent increase in insulin secretion, but these 
0
5
10
15
20
25
30
NCC 1 2 3 4
In
su
lin
 (
n
g/
m
l)
Treatment
Extract
THC 
ANA
RIM
* 
# 
# 
* 
85 
  
levels were lower than that of NCC. Rimonabant had similar insulin levels at 
all concentrations, but these were lower than the NCC. 
 
Figure 7.3: Stimulated insulin secretion of INS-1. Error bars indicate SEM (n=6). 
#
 
p<0.01 relative to NCC 
 
7.2.4 Insulin content 
The extract treatment, 0.25-1 µg/mL, resulted in similar levels of insulin 
compared to NCC, except at 0.5 µg/mL where there was a 2-fold increase in 
insulin content compared to NCC (figure 7.4). There was significantly higher 
insulin content at 3 and 0.025 µg/mL THC and anandamide, respectively, 
compared to NCC (p<0.05). Anandamide treatment exhibited the same 
concentration dependent decrease in insulin content as THC. Rimonabant 
resulted in significantly higher insulin content at 0.25 and 0.75 µg/mL 
compared to NCC (p<0.01). 
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Figure 7.4: Insulin content of INS-1. Error bars indicate SEM (n=6). *p<0.05, 
# 
p<0.01 
treatment relative to NCC. 
7.2.5 Stimulatory index 
The stimulatory index gives an indication of the sensitivity of the beta cells to 
glucose stimulation. At the lowest concentration, none of the cannabinoids 
stimulated insulin secretion. The extract does not stimulate insulin secretion 
higher than that of the NCC. THC at 5 µg/mL significantly stimulated insulin 
secretion (p<0.05). Anandamide did not promote insulin secretion with levels 
remaining at 60 % of NCC. Rimonabant at 1 µg/mL stimulated secretion to 
levels similar to NCC. 
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Figure 7.5: Stimulatory index of INS-1. Error bars indicate SEM (n=6). *p<0.05 treatment 
relative to NCC. 
7.3 Oxygen consumption studies 
Oxygen consumption studies were performed on cells cultured in media 
containing 11.1mM glucose. The cannabinoids had no significant effect on 
oxygen consumption with oxygen consumption remaining similar to NCC for 
all the cannabinoids. With the addition of oligomycin, there was an increase in 
oxygen consumption relative to NCC for the cannabinoids with rimonabant 
showing a significant increase relative to NCC (p< 0.05). 
 
Figure 7.6: Effects of cannabinoids on oxygen consumption in INS-1 cells at 11.1mM 
glucose. Error bars indicate SEM (n=3). *p<0.05 treatment relative to NCC. 
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7.4 RT-PCR studies 
Gene expression of insulin and Glut-2 were evaluated using RT-PCR. 
7.4.1 Glut-2 
The extract and THC treatments significantly up-regulated Glut-2 (figure 7.7) 
expression relative to NCC (p<0.01). Anandamide treatment resulted in 
similar Glut-2 levels as NCC, while Rimonabant moderately increased Glut-2 
expression. 
 
Figure 7.7: Glut-2 gene expression in INS-1 cells. Error bars indicate SEM (n=4). 
# 
p<0.01 treatment relative to NCC. 
7.4.2 Insulin 
The cannabinoids did not significantly influence insulin gene expression in 
INS-1 cells in relation to NCC, by either causing a marginal increase or 
marginal decrease or no change (figure 7.8). THC and anandamide  
upregulated insulin expression relative to NCC, while Rimonabant decreased 
insulin expression  
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Figure 7.8: Insulin gene expression in INS-1 cells. Error bars indicate SEM (n=4). 
7.5 Western blot analysis 
After exposure to the cannabinoids, proteins lysates were analyzed for Glut-2 
(figure 7.9). The extract promoted a 3-fold increase in Glut-2 compared to the 
NCC. THC promoted a 1.4-fold increase in Glut-2. Anandamide promoted a 
1.8-fold increase in Glut-2 while rimonabant had less than a 1-fold increase in 
Glut-2 expression relative to NCC. 
  
INS 1  
Figure 7.9:  A typical set of Western blot results of the various cannabinoid treatments 
with a Glut-2 antibody raised against INS 1 cell lines. Bands observed correspond to a 
molecular weight of 58 kDa. Lanes: (1) NCC, (2) Extract, (3) THC, (4) ANA and 5 (RIM) 
(n=3). 
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Chapter 8: Discussion of insulin secretion results 
Insulin is a key hormone involved in blood glucose homeostasis and its 
deficiency contributes to the etiology of diabetes mellitus (Juan-Pico et al., 
2006). Stimulation of insulin secretion from pancreatic islets by glucose and 
other fuels is associated with increased respiration. The stimulus-secretion 
coupling mechanism involves an increase in intracellular free Ca2+ (Civelek et 
al., 1996). 
Glucose is the major nutrient regulator of pancreatic β-cell function and 
coordinately regulates insulin gene expression, insulin biosynthesis, and 
insulin secretion. Glucose controls all steps of insulin gene expression, 
including transcription, preRNA splicing, and mRNA stability. The β-cell 
adapts the rate of insulin secretion to fluctuations in the blood glucose 
concentration. Glucose equilibrates across the plasma membrane and is 
phosphorylated by glucokinase, which determines the rate of glycolysis and 
the generation of pyruvate (Maechler and Wollheim, 2000).  
 
In glucose-stimulated β-cells, Ca2+ concentration rises resulting in insulin 
secretion which is biphasic, i.e. a transient first phase and a second, 
sustained phase (Maechler and Wollheim, 2000). Pancreatic β-cells 
synthesize insulin and secrete it at appropriate rates to maintain blood 
glucose levels within a relatively narrow range. When glucose levels 
decrease, less insulin and more glucagon is released by the pancreas and 
targets the liver. The effect of glucagon is to make the liver release the 
glucose it has stored in its cells into the blood stream, with the net effect of 
increasing blood glucose (Henquin, 2000).   Glucose does not increase insulin 
secretion in the absence of extracellular Ca2+ (Henquin, 2000). 
 
Cytosolic calcium is a major mediator governing the amount of insulin 
released in response to a glucose challenge (Mears, 2004). The effect of 
calcium in mediating energy turnover has been a point of particular interest 
due to the role of the metabolic coupling factors ATP and ADP in regulating 
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calcium influx by closing ATP-sensitive K+ channels (KATP channels). It is 
established that calcium influx has an effect on oxygen consumption but the 
mechanism mediating the interaction regarding the amount of ATP generated 
in response to glucose utilization by the calcium-dependent process, is still 
unclear. The processes that govern ATP usage in β-cells, and the 
contributions of protein synthesis, ion transport, and exocytosis of insulin 
granules to total glucose-stimulated ATP production have not been quantified 
extensively to date (Sweet and Gilbert, 2006). 
The data on the effects of the ECS in the pancreas are less extensive than 
data collected on other tissues but some evidence exists that blockade of CB1 
receptors may exert direct effects on the pancreas that modulate energy 
homeostasis (Matias et al., 2006). A recent study by Matias et al. (2007) 
showed that pancreatic cultured β-cells, under conditions mimicking 
hyperglycaemia, also presented elevated levels of both AEA and 2-AG, 
suggesting that under these conditions, such as during pre-diabetes, T2DM 
and obesity, the ECS in β-cells becomes upregulated.  
 
Human islets express CB1 and CB2 mRNA and CB1 and CB2 proteins, as 
well as the machinery involved in synthesis and degradation of 2-AG. In vitro 
experiments revealed that CB1 stimulation enhanced insulin and glucagon 
secretion, while CB2 antagonist lowered glucose-dependent insulin secretion, 
showing these cannabinoid receptors to be functional (Bermedez-Silva et al., 
2008). 
 
In the rat insulinoma β-cell line, CB1 and CB2 were expressed on both α- and 
β-cells (Bermudez-Silva et al., 2007).  Juan-Pico et al. (2006), using mouse 
islets, showed that stimulation of CB2 receptors reduces insulin release 
through inhibition of calcium transients, whereas CB1 receptors, exert a 
similar effect to a much lesser extent (Matias and Di Marzo, 2007). The 
reduction in insulin secretion is similar to that found in this study. 
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Laychock et al. (1986) showed that isolated pancreatic islets from rat secrete 
insulin in response to glucose or THC. THC stimulated the basal release of 
insulin and also increased the secretory response to glucose. Anandamide 
inhibited glucose-induced insulin secretion from mouse pancreatic islets and 
inhibited glucose-induced cytosolic Ca2+ oscillation in mouse pancreatic β-
cells (Nakata and Yada, 2008). These findings support the data observed in 
this study. The mechanism for the variation in secretion to the exogenous and 
endogenous CB1 agonist remains unknown. 
The effects of the cannabinoid treatments on chronic insulin secretion 
revealed that the cannabinoids had an overall suppressive effect on insulin 
secretion (figure 7.1). Exceptions to this were the 0.25, 3 and 0.5 µg/mL of 
extract, THC and anandamide, respectively. At these concentrations those 
cannabinoids increased chronic insulin secretion. 
Under basal conditions (3.3 mM glucose) the extract increased insulin 
secretion albeit not significantly (figure 7.2). THC standard suppressed insulin 
secretion in a concentration dependent manner, under basal conditions. 
Anandamide partially suppressed insulin secretion but with an increase in 
anandamide concentration insulin release was stimulated to levels similar to 
the control. Rimonabant stimulated insulin secretion at 0.25 µg/ml and 
suppressed secretion at higher concentrations. 
High glucose exposure in the INS-1 cells stimulated an increase in insulin 
secretion by NCC (figure 7.3). The cannabinoids suppressed insulin secretion 
by 50 % relative to the NCC. However, THC at 0.5 µg/mL stimulated insulin 
secretion to 66% of control. 
Insulin content (figure 7.4) was enhanced after cannabinoid treatment at lower 
concentrations, but at higher concentrations levels were similar to the NCC 
except for rimonabant  which had significant increases in insulin content 
relative to NCC at 0.025 and 0.5 µg/mL. 
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Results from the stimulatory index (figure 7.5) showed that the cannabinoids 
ability to stimulate insulin secretion was limited to THC (0.5 µg/mL) and 
rimonabant (1 µg/mL). The extract and anandamide suppressed insulin 
secretion. Nakata and Yada (2008) showed that anandamide (10-6 - 10-5 M) 
and CB1 agonists (10-6 M) inhibited glucose-induced increases in [Ca2+] in 
mouse pancreatic β-cells which could attribute to the lack of insulin secretion. 
Juan-Pico et al., (2006) found that anandamide regulated intracellular Ca2+ 
concentrations, provoking a decrease in the amplitude of glucose-induced 
intracellular Ca2+ oscillations and that anandamide induced a change in the 
oscillatory pattern in 33% of the islet tested. A decrease in the amplitude of 
Ca2+ signals indicates a decreased insulin release (Juan-Pico et al., 2006). 
The actions of CB1 agonists are also mediated through the Gi proteins in 
several cells. The activation of Gi by cannabinoids leads to inhibition of 
adenylate cyclase and a reduction in cytosolic cAMP, which could in turn 
suppress L-type Ca2+ channels in β-cells, resulting in inhibition of glucose-
induced intracellular Ca2+ concentration increases and insulin release (Nakata 
and Yada, 2007). 
Glucose sensing by the β-cell is achieved through expression of specific 
glucose transporters and key metabolic enzymes that are poised to stimulate 
oxidative phosphorylation efficiently. Stimulation of insulin secretion by 
glucose involves the enhanced synthesis of ATP by mitochondria, and closure 
of ATP-sensitive K+ channels, believed to be due to an increase in the 
ATP/ADP ratio. Subsequent depolarization of the plasma membrane then 
opens voltage sensitive (L-type) Ca2+ channels causing insulin-containing 
vesicles to fuse at the plasma membrane (Xavier et al., 2002; Kennedy et al., 
1996). 
 
As a mitochondrion-targeting agent, oligomycin inhibits mitochondrial F0F1-
ATPase. In addition, oligomycin inhibits ATP synthase by blocking its proton 
channel, which is necessary for oxidative phosphorylation of ADP to ATP. 
Electron transport ceases but there is an increase in the proton gradient, and 
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electron transport eventually stops because of the difficulty of pumping any 
more protons against the steep gradient. In oxidative phosphorylation 
research, it is used to prevent state 3, phosphorylating respiration (Nakata et 
al., 1995). 
Oxygen consumption was not significantly increased nor decreased by 
cannabinoid treatments (figure 7.6). Inhibition of ATPase by oligomycin 
decreased oxygen consumption in the NCC by 50%. The reduction in oxygen 
consumption after oligomycin addition was similar to the NCC for the 
cannabinoid treatments. Rimonabant significantly improved oxygen 
consumption relative to the NCC.  
The extract and THC significantly up-regulated Glut-2 gene expression 
relative to the NCC while anandamide and rimonabant treatment resulted in 
Glut-2 gene expression levels similar to the control (figure 7.7). This increased 
gene expression was accompanied by increased protein expression of Glut-2 
(figure 7.8) for the extract (3-fold) and THC (1.4-fold) relative to the NCC. 
Anandamide promoted more Glut-2 protein than THC did, even though it did 
not up-regulate Glut-2 gene expression to the same level as THC.  
The stimulatory index indicates a reduction in insulin secretion. This 
suppression of insulin secretion can be contributed to factors other than Glut-
2 regulation and insulin as these proteins were expressed at levels similar to 
NCC. Gene expression of insulin indicates that the cannabinoids did not 
significantly increase transcription of insulin which could explain the inability of 
cannabinoids to stimulate insulin secretion. However, there were similar or 
higher levels of insulin content in the cannabinoid treated cells.  
The cannabinoids effects on insulin secretion were varied. The ability of the 
cannabinoids to suppress insulin secretion at low glucose levels is indicative 
of a positive effect with regards to glucose homeostasis. However their 
inability to stimulate insulin secretion upon glucose stimulation could 
contribute to hyperglycaemia. THC was the only cannabinoid to stimulate 
insulin secretion. The influence on intracellular calcium could contribute to the 
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effect the cannabinoids have on insulin secretion and the CB2 receptor could 
be the key to stimulating insulin secretion. 
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Chapter 9: Conclusions and future research 
The majority of cannabinoid research to date has been focused on the 
endogenous cannabinoid systems’ contribution to pathologies associated with 
the metabolic syndrome such as obesity. The aim of this work was to 
investigate the effects of cannabinoids in an in vitro insulin resistance model 
and to evaluate their effects in insulin secretion. 
The extract and THC proved to be efficient in reducing the complications 
associated with insulin resistance in 3T3-L1 and C2C12 cells. The mechanism 
by which they bring about this positive physiological response could be 
attributed in part to the up-regulation of PI3K. The extract and THC thus have 
the potential to be an insulin sensitizing agents. The results for rimonabant in 
insulin resistant cells differ from those associated with rimonabant as a 
treatment in obesity; however rimonabant still has therapeutic potential in the 
treatment of T2DM. 
The cannabinoids effect on insulin secretion was not significant. Only THC 
proved effective in stimulating insulin secretion. These results were based on 
cells cultured under normoglycemic conditions, and is therefore not indicative 
of a diabetic state.  Future studies on the effects of cannabinoids on insulin 
secretion need to include hyperglycemic conditions so as to determine 
whether the cannabinoids have an equally protective role on pancreatic β-
cells. 
This study did not evaluate the effects of cannabinoid treatment on calcium 
flux to determine whether that is the underlying reason for the reduction in 
insulin release.  
For future investigations an insulin resistant animal model should be used in 
order to evaluate the effects of the cannabinoids within a physiological system 
to determine if the beneficial effects of the cannabinoids, as observed in the in 
vitro model, are still maintained. Insulin signaling pathways should also be 
examined more extensively to determine the impact of the cannabinoids on 
insulin secretion within a diabetic or insulin resistant model. 
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Appendix A 
Table A: RT-PCR CT data of 3T3-L1 cells 
Sample IRS1 Glut4 Cyclo A ywaz UBC 
FC1                  13 9.4 25.6 26.5 18.4 
FC1                  13.2 10.6 25.2 26.52 18.9 
FM1                  13.2 13.1 25.1 26.3 18.6 
FM1                  13.4 13.1 25.1 26.29 18.2 
FTF1                 14.8 12.7 25.2 26.7 18.5 
FTF1                 13.4 12 26 26.4 18.4 
FE1                  10.1 11.8 25.5 26.33 18.5 
FE1                  10.4 11.2 25.4 26.5 18.3 
FTHC1                9.2 10.1 25.3 26.71 18 
FTHC1                9.3 10.1 25 26.77 18.7 
FA1                  13 14.8 25.5 26.4 18.6 
FA1                  14.8 13.8 26.4 25.9 18.4 
FR1 13.1 12.6 25.3 26 18.1 
Fr1 13.2 12.3 25.6 25.89 18 
FC2                  13.3 9.6 25.3 25.91 18.4 
FC2                  13.4 9.6 25.8 26 18.4 
FM2                  13.3 13.1 25.4 26.6 18.2 
FM2                  14.3 13.2 25 26.54 18.6 
FTF2                 15 10.2 25.1 25.8 18.6 
FTF2                 13.5 9.4 25.8 25.98 18.1 
FE2                  10.6 8.4 25 26.1 18.1 
FE2                  10.2 7.4 25.7 26.5 18.3 
FTHC2                9.5 6.3 25.1 26.55 18.7 
FTHC2                9 7.6 25.6 26.67 18.8 
FA2                  13.3 11.8 25.3 26.69 18.8 
FA2                  13 10.8 25.8 25 18.4 
FR2                  13.2 11.7 26.4 25.8 18.9 
FR2                  12.8 11.2 25.7 26 18 
FC3                  13.4 9.4 25.6 26.7 18.9 
FC3                  12.8 9.8 25.5 25.9 18.2 
FM3                  12.9 11.5 25.7 25.8 18 
FM3                  6.5 11.7 25.2 25.77 18.3 
FTF3                 13.3 10.9 25.8 26.81 18 
FTF3                 12.6 9.9 25.6 26.67 18.1 
FE3                  10.3 10.7 25.6 25.98 18.13 
FE3                  10.4 9.9 26.2 25.65 18.6 
FTHC3                9.9 11.1 25.6 25.77 18.7 
FTHC3                9.1 12.1 25.1 25.62 18.5 
FA3                  13.3 12.9 25.7 25.79 18.8 
FA3                  13.4 11.5 25 25.89 18.4 
FR3                  13.1 11.4 25.6 26.9 18.32 
FR3                  12.9 11.9 25.9 26.91 18.9 
STD               13.1 13.8 25.1 30.1 18.2 
STD               13.5 13.2 25.7 30 18.7 
calibrator 16.73 17.8 22.3 32.8 17.7 
      22.45 33.5 16.7 
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Table B: RT-PCR CT data for C212 cells 
Sample IRS1 Glut4 Cyclo A ywaz UBC 
cC1                  12.8 7.7 24.4 24.6 18.4 
cC1                  13.1 8 23.9 24.1 18.9 
cM1                  12.6 8.3 24.6 24.1 18.6 
cM1                  16.8 9 24.5 23.8 18.2 
cir1                 13.4 11 24.5 23.7 18.5 
cir1                 13.3 11.2 23.8 23.8 18.4 
cE1                  10.2 7.5 24.5 23.8 18.5 
cE1                  10.2 8.1 24.3 24.1 18.3 
cT1                  13.1 8.7 24 23.9 18 
cT1                  13.2 8.1 24.7 24 18.7 
cA1                  13 17.4 24.6 23.9 18.6 
cA1                  12.9 17 24.4 24.2 18.4 
cR1                  13.5 9.9 24.1 24 18.1 
cR1                  15.7 8.6 24 24.3 18 
cC2                  13 11.7 24.4 23.9 18.4 
cC2                  15.8 11 24.3 24.2 18.4 
cM2                  13.2 9.7 23.9 24 18.2 
cM2                  14.7 9.3 23.8 24.3 18.6 
cIR2                 15 14 24.6 24 18.6 
cIR2                 16 14.1 24.1 24.1 18.1 
cE2                  13.2 8.3 24.1 24.13 18.1 
cE2                  13.2 8 23.8 23.6 18.3 
cT2                  14.7 8 23.7 23.7 18.7 
cT2                  13.3 8.2 23.8 24.5 18.8 
cA2                  15.9 18 23.8 23.8 18.8 
cA2                  9.4 18.7 24.1 24.4 18.4 
cR2                  12.6 10.2 23.9 23.9 18.9 
cR2                  13.4 9.1 24 24.6 18 
cC3                  14.8 18.6 23.9 24.5 18.9 
cC3                  13.4 17.6 24.2 24.5 18.2 
cM3                  26.5 8.2 24 23.8 18 
cM3                  14.8 9.6 24.3 24.5 18.3 
cIR3                 13.1 9.2 24 23.6 18 
cIR3                 14.5 9.3 24.1 23.7 18.1 
cE3                  15.7 8 24.13 24.5 18.13 
cE3                  13.3 7.9 23.6 23.8 18.6 
cT3                  13.4 9 23.7 24.4 18.7 
cT3                  13.3 10.1 24.5 24.32 18.5 
cA3                  13.6 10 23.8 23.9 18.8 
cA3                  13.2 8.4 24.4 24.7 18.4 
cR3                  9.6 9.1 24.32 24.6 18.32 
cR3                  13.3 10.6 23.9 24.4 18.9 
STD               13.1 16.8 24.2 26.1 18.2 
STD               13.5 16.9 24.7 26.2 18.7 
calibrator 15.73 15.1 22.3 28 17.7 
      22.45 28.1 16.7 
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Table C: RT-PCR CT data for INS 1 cells 
Sample Insulin Glut 2 Cyclo A GAPDH TUB 
c1                 17.1 33.2 22.6 31.1 21.1 
c1                 17.5 32.9 23.1 31 21.3 
e1                 18.3 32.7 23.11 30.7 21.3 
e1                 17.7 32.8 23.1 30.9 21.4 
t1                 16.7 28.2 22.3 30.7 20.71 
t1                 17.3 28.3 23 31.3 20.6 
a1                 16.7 29.8 22.9 31 20.7 
a1                 16.7 28.3 23 30.72 21.1 
r1                 16.1 31.5 22.7 30.6 20.5 
r1                 17.1 32.3 23 31.6 20.3 
c2                 18.6 29 25.6 31.11 21.4 
c2                 17.5 28.6 26.1 30.62 21.1 
e2                 17.9 28.1 22.6 31.2 20.95 
e2                 17.7 27.9 23.1 30.65 21.4 
t2                 18.6 27.3 23 30.7 21.7 
t2                 18.2 26.2 22.2 31.1 21.65 
a2                 18.7 28.9 22.5 31.2 21 
a2                 18.7 29.9 22.4 30.7 21.2 
r2                 17.7 30.7 22.3 30.8 21 
r2                 16.7 31.1 22.5 30.8 20.6 
c3                 17.1 27.8 23.1 31.3 20.8 
c3                 17.7 28.1 23.1 30.82 21 
e3                 16.2 26.7 23.1 30.62 20.9 
e3                 16.8 26.4 23.1 30.8 20 
t3                 17.9 26.8 23 31.14 20.91 
t3                 18.2 27.5 22.6 31.1 20.93 
a3                 17.5 28.5 22.5 30.7 21.21 
a3                 17.7 27.5 23.2 31 20.9 
r3                 17.7 32.9 23.2 30.8 20.8 
r3                 17 32.5 23.1 30.71 20.91 
STD               11.4 30.9 23.2 31.37 22.7 
STD               10.9 31.1 23.24 31.7 22.8 
calibrator 11.93 32.73 22.3 32.73 20.9 
  12.2 33.82 22.45 33.82 21.8 
 
